The Jacinto Convit World Organization (JCWO) is a U.S. nonprofit and nongovernmental organization founded in 2014 to contribute primarily to important areas of public health, such as cancer and endemic diseases, around the world. The organization is named after Dr. Jacinto Convit (1913-2014), a Venezuelan and world renowned physician, scientist, and humanist, who benefited millions worldwide with his medical studies during his career span of more than 70 years. JCWO serves as a platform to preserve, promote, and continue the legacy and scientific efforts of Dr. Convit through scientific, educational, and social programs.

Our President
Ana Federica Convit
As a founder, she has been led efforts to continue Dr. Convit’s legacy and philosophy since 2010 when she founded a small non-profit organization (Asoinmunocáncer) to continue Dr. Convit’s research on a therapeutic vaccine for breast cancer. A couple of years later, in 2012, she founded Fundación Jacinto Convit (FJC), absorbing the prior organization and committing to preserve, continue and expand Dr. Convit’s legacy, promoting his scientific research, educational and social projects.

As Secretary-General of FJC, Ana Federica has worked in the development of pioneer programs with high social impact in the areas of molecular diagnostics, development of new immunotherapy treatments, educational programs, and more recently a training program for students and professionals from all regions of her native country. Currently, she leads a group of more than 15 professionals (main staff) in different areas, making sure that both organizations FJC and JCWO advance in their strategic goals and continue to grow as successful institutions.
Board of Directors

The board of directors is conformed by highly experienced professionals from different areas, who have come together to regulate the development and activities of JCWO. Its main duty is to revise and give further response and approval of every legal engagement, project, publication, and any activity in which JCWO is engaged or wishes to engage. As well, the board of directors is responsible for addressing all reported violations relating to corporate accounting practices, internal controls or auditing.

JCWO constituted its board of directors in 2015, conformed by six (6) directors of different professions, who also contributed to the legal development of the organization. In 2017, two of the directors had to step down from their cooperation with JCWO due to conflicts of interest with their permanent jobs, and new members came on board. The current board is presented below.

Dr. Antonio Convit
NYU Langone Health
Professor, Department of Psychiatry
Professor, Department of Medicine
Professor, Department of Radiology

Dr. Antonio J Convit, MD is a Doctor primarily located in New York, with more than 30 years of experience in psychiatry research, currently focused on the impact of obesity and metabolic dysregulation from obesity on cognition and brain integrity. For the last 15 years, the research group he leads have centered in utilizing in vivo MRI imaging techniques, neuropsychological test performance, and endocrine and inflammatory markers to understand how the brain is affected by obesity and associated metabolic diseases.
Dr. Rafael Convit  
MedStar Health  
Plastic Surgery & Breast Reconstruction  
General Plastic Surgery  
Aesthetic & Cosmetic Plastic Surgery  

Dr. Rafael Convit is a plastic surgeon in Washington, District of Columbia, affiliated with multiple hospitals in the area, including MedStar Georgetown University Hospital and MedStar Washington Hospital Center. He has more than 20 years of experience in the medical practice, being one of the main plastic surgeon in the area. His work is currently focused on breast cancer reconstruction in a multidisciplinary team at The Cancer Institute of Medstar Washington Hospital Center, where he uses a holistic approach to treat his patients. He has leadership roles at the hospitals where he practices and is on the Board of Directors of Medstar National Rehabilitation Hospital.

Dr. Lilia Correa  
Dr. Correa, MD is fellowship-trained in dermatology and Mohs surgery, with a specialized training in confocal microscopy, and more than 15 years of experience in the dermatology practice. She has earned a number of awards, with plenty co-authoring publications and presentations; participating also in multiple clinical trials involving laser related treatments, cosmeticals and body contouring.

Mauricio Aranguren  
Executive Director - UBS AG Wealth Management Americas  

Mauricio Aranguren is a professional in Business Administration, currently an Executive Director in the UBS Wealth Management for the Americas, with a licensed client adviser that provides advice to families and related institutions. He has been recognized as a Top Producer within his region for several years. He is a member of the Chairmans Council 2018,
and previously a member of the Presidents Council 2017; also named a council member for the Wealth Management International Advisory Committee for 2016-2017.

Our Work

JCWO relies on the laboratory facilities of its sister organization, Fundación Jacinto Convit (FJC), located in South America. JCWO seeks to project at a global scale, part of the work that is being conducted by FJC. In this sense, its current international efforts are focused on two programs: i) Cancer Immunotherapy, for the development of new immunotherapies to treat breast cancer, as well as other solid tumors, and ii) Molecular Diagnostics to support the early and precise detection of various pediatric cancers and other relevant infectious diseases that are endemic in the Latin American region. All programs are free of cost for the patients, and are targeted to the larger population that lack the resources to access high quality diagnostics and innovative (or conventional) therapies. This, as part of JCWO’s philosophy and its mission to generate a positive impact in the global health system.

JCWO’s primary objective is focused on continuing the development of a personalized immunotherapy for breast cancer, designed by Dr. Convit during his last years of life, aiming to soon enter the clinical phase. This vaccine is a result of Dr. Convit’s previous successful experiences with the therapeutic vaccines for Leprosy and Leishmaniasis, diseases that share similarities with cancer in the immune contributions to the pathology. To advance in the implementation of this therapy and support molecular diagnostics, JCWO is currently making efforts on building financial support and collaborative networks with US and European companies, health and research centers, academia, NGOs, among other institutions, as well as connecting with individual donors that want to support our work. Integrating these efforts will strengthen and expand the outreach of JCWO’s programs and increase the impact in the healthcare system of the region and around the world, providing newly, effective and accessible.
JCWO continues Dr. Convit’s philosophy on the desire to help the most vulnerable, and provide services that are accessible to the mass population. Hence, promoting access to high quality health services to underprivileged population in low-income countries.

Main Objectives

- Through the scientific, educational, and social programs carried out in partnership with Fundación Jacinto Convit we aim to preserve, promote and continue Dr. Convit’s legacy.
- Project at a global scale the work that is being conducted in Venezuela within the studies on breast cancer immunotherapy, which intend to achieve an effective, safe, and personalized immunotherapy for this disease.
- Support the continuation of the free of cost molecular diagnostic service that is provided by FJC in Venezuela for various pediatric cancers and other relevant infectious diseases for pediatric patients.
- Build collaborative networks with health and research centers, academia, NGOs and multilaterals across the US and Europe, to help sustain and achieve the ongoing projects of JCWO and its partner FJC.

In accordance with JCWO’s main objectives, during these years the organization focused on building its organizational base while advancing to reach its strategic goals; continuously evolving on its specific objectives and activities. This helped to create a solid and transparent non-profit organization as required by US law.

JCWO’s Story line

2014
Pro bono engagement with DLA Piper
ANNUAL REPORT  
2014-2017

DLA Piper is a multinational law firm, regarded as one of the largest and most prestigious law firms in the world, in terms of revenue and lawyers; located in more than 40 countries throughout the Americas, Asia Pacific, Europe, Africa, and the Middle East. JCWO applied for a pro bono service with DLA Piper in Palo Alto, California in 2012 and was approved to help incorporate the NGO in California and apply for federal tax exemption. After a long due diligence process, collection of information and applications to government entities, JCWO was incorporated and classified as 501(c)(3) public charity. In January 23rd 2014 JCWO received an engagement and conflict waiver letter from DLA. This engagement consists of a legal representation by DLA Piper in connection with JCWO’s constitution in the State of California, and other routine corporate matters, such as merges and acquisitions, take overs, and other change-in-control issues and transactions. Additionally, it includes commercial transactions, or representation in litigation, intellectual property matters, bankruptcy or taxation matters, administrative proceedings, legislative or policy matters. In the course of this representation, DLA Piper keeps JCWO informed about the status of the legal engagement, and promptly complies with the organization’s request of information.

Incorporation of Jacinto Convit World Organization.
The Articles of Incorporation of Jacinto Convit World Organization were defined under a legal document signed by the incorporator Mr. Jonathan D. Frohnmayer in January 24th 2014, and filed in the Secretary of State of the State of California in January 27th 2014.

In February 7th 2014 JCWO was incorporated under the California Nonprofit Public Benefit Corporation Law for the purposes set forth in the Articles of Incorporation, including but not restricted:

1. To conduct, support, and facilitate medical research and diagnosis of different types of cancer and tropical infectious diseases, among other diseases, affecting vulnerable populations in Venezuela, where Dr. Jacinto Convit has based his medical research, and around the world.
2. To build collaborative networks with similarly-focused national and international research groups and establish an international platform that will facilitate the foregoing charitable purposes of the corporation.

3. To raise, solicit, accept, hold, invest (in trust or otherwise), reinvest, and administer any gifts, legacies, bequests, devises, funds and property of any sort or nature from individuals and institutions, and use, expend, or donate the income or principal thereof for, and devote the same to, the foregoing charitable purposes of the corporation.

Election of Directors and definition of the bylaws

In February 18th 2014, JCWO’s board of directors was created, and its representatives were elected. Before this action, JCWO had a sole incorporator with the corresponding responsibilities in accordance with the California Nonprofit Corporation Law, Mr. Jonathan D. Frohnmayer, who upon completion of this action had no further responsibilities or obligations to the Corporation in his capacity as sole incorporator. Each of the following persons were elected as directors of the Corporation to serve until his or her successor is duly elected and qualified or until he or she resigns, is removed, or is otherwise disqualified from serving as director of the Corporation:

- Antonio Convit
- Rafael Convit
- Timothy McGraw
- Ana Federica Convit
- Lilia Correa
- Carlos Rivas

At the same time, the bylaws of JCWO were outlined in a legal document signed by the current elected and acting Secretary at the moment, Mr. Carlos Rivas.
Statement of information filing

Every California nonprofit, credit union and general cooperative corporation must file a Statement of Information with the California Secretary of State, within 90 days of registering with the California Secretary of State, and every two years thereafter during a specific 6-month filing period based on the original registration date. Therefore, JCWO as an organization registered in the State of California, filed a Statement of Information in February 20th 2014, with the number EW81577. This filing was supported by the following officers, indicating their corresponding position at the moment.

✓ Ana Federica Convit – Chief Executive Officer
✓ Carlos Rivas – Secretary
✓ Alicia Asensio – Chief Financial Officer

2015

Tax exemption

In January 2014 with the support of DLA Piper, the request for tax exemption was introduced to the Internal Revenue Service (IRS) of the Department of the Treasury in the US, obtaining the Employer Identification Number (EIN) 46-4905774. In October 2015 the IRS letter of determination was received, where it was established that JCWO is exempt from federal income tax under Internal Revenue Code (IRC) Section 501 (c) (3). This means that any donor can deduct contributions they make to JCWO under IRC section 170. Also, JCWO qualifies to receive tax deductible bequests, devises, transfers, or gifts under the Section 2055, 2106 or 2522.

Resolutions from the first board of directors meeting

In August 5th 2015 the first annual board of directors meeting was held, where resolutions regarding the following topics were adopted:
ANNUAL REPORT
2014-2017

- Articles of Incorporation
- Bylaws
- Election of Officers, defining Ana Federica Convit as President and Treasurer, and Carlos Rivas as Secretary.
- Bank Resolutions, defining the specific authorizations of the President and Treasurer.
- Establishment of principal office for the business of the Corporation in the following address: 508 Misty Oaks Dr. Pompano Beach, FL 33069.
- Incorporation Expenses
- Accounting year, beginning on January 01 and ending in December 31.
- Authorization to file with governmental agencies
- Insurance matters
- Corporate policies
- Enabling Resolutions

2016
Strategic alliance with Baker McKenzie
Baker Mckenzie is the world’s strongest law firm with functional outsourcing operations, and located all over the world. Corporate Social Responsibility is an integral part of their work, aiming to make a lasting difference for many of today’s social and economic challenges. In 2016 a collaboration agreement was signed with our sister organization FJC, in which Baker McKenzie gives their wide legal advice as a pro-bono service. After the partnership agreement was signed between FJC and JCWO, Baker McKenzie US began to directly support JCWO.

2017
Strategic partnership agreement with Fundación Jacinto Convit
Fundación Jacinto Convit (FJC) is a non-profit charitable and social welfare institution that preserves, protects and continues the legacy of Dr. Jacinto Convit, and whose purpose is to organize, maintain and manage scientific and healthcare research laboratories, among other activities. Under this partnership agreement signed in January 2017, FJC and JCWO established a strategic partnership in order to work together to promote Dr. Convit’s legacy worldwide, making progress in public health, scientific research, assistance programs, and teaching, and producing a scientific and social impact on the most vulnerable populations. Also, mainly for the procurement, negotiation, maintenance and strengthening of networks, collaborations and alliances with health, and research centers worldwide, with the academia, NGOs and other governmental and multilateral organizations across the world. With this action, JCWO and FJC became sister organizations that support each other, within the best definition of teamwork.

Strategic alliance with Camero & Company CPA, PA.
Camero & Company is a CPA firm specializing in international and national corporate solutions, including superior tax, accounting, business, and attestation services. In 2017 an alliance was established in which Camero & Company provides their services in accounting, tax filings and other federal and state requirements as a pro-bono service.

International application under the Patent Cooperation Treaty (PCT)
A main objective of JCWO and FJC is to protect Dr. Convits legacy, more specifically his proposal of a cancer immunotherapy. Therefore, in May 2017 after a patent request was filed by FJC in Venezuela, the intellectual property was shared with JCWO in which both entities became co-owners of the intellectual property and JCWO as a member country of the PCT, filed (with the representation of Baker McKenzie) its application of: “An immunogenic composition for the treatment of cancer and methods of preparing the same”. The international publication of this application was obtained on November 16th 2017 with the
ANNUAL REPORT
2014-2017

International Publication Number WO 2017/197005 A1. This gives JCWO a priority worldwide on the protection of the intellectual property for the following year, until November, 16th 2018.

Consulting agreement with Biologics Consulting
Biologics Consulting is a full-service regulatory and product development consulting firm for biologics, pharmaceuticals and medical devices. It has become the go-to consulting partner for companies large and small seeking to bring innovative, safe and effective products to market within the U.S., and claim to hold themselves to the highest standards of professionalism, scientific practice and ethics, delivering innovative solutions and extraordinary results for clients across the globe.

In an effort to continue the development of the cancer vaccine designed by Dr. Convit, and the main aim to advance into the clinical phase, JCWO searched for consultancy and recommendations in this regard. In this process, a consulting agreement was signed with Biologics Consulting, obtaining an estimated cost for their service to conduct a Gap Analysis and Advise on Regulatory Strategy. A complete or partial pro-bono request was made, with an unfortunate negative response. Therefore, this agreement did not involve any further actions but some pinpoints were provided by them in regards to the procedure to enter a clinical phase.

Donations
JCWO is now a reality thanks to a combined effort of multiple institutions and individuals that strongly believe in the necessity of making this project a reality. Late in 2017, JCWO was registered in Amazon Smile, in which the organization can receive a donation of 0.5% of each purchase made by customers who choose JCWO as a beneficiary organization. This helped JCWO to obtain small frequent donations from the general public.
JCWO’s team

In November 2017, JCWO began its actual work starting with international efforts to build collaborative networks and advance in the inclusion of Dr. Convit’s vaccine into the clinical phase. For this it brought in new members as staff to carry out the work under the leadership of JCWO’s President. An international representative was appointed, and then a research collaborator.

Dr. Eglys González, previous Research Coordinator of FJC from 2013 to 2015, and scientific adviser for FJC until late 2017, came on board to lead international efforts as the International Representative of JCWO. She is responsible for the international approach to networking, project development and social media management. Also works in the development of the organizational base to consolidate the non-profit organization.

Dr. María José Godoy, previous Research Coordinator of FJC from 2015 to 2017. When she moved to the US she became a main research collaborator for JCWO. As a researcher she contributes with the continuation of the development of Dr. Convit’s immunotherapy, by publishing scientific articles and advising on future studies.
Specific objectives and activities

1. Set up collaboration agreements with clinics where the immunotherapy can be used in patients, allowing us to follow up and register the data related to the health progress of treated patients. Hence determining the effectiveness of the vaccine.

Activities:
- Search in the web for clinics in Europe that allow application of developing personalized vaccine treatments.
- Make contact with the clinics found and set up meetings to propose and arrange the use of Dr. Convits vaccine.
- Arrange a proposal of collaboration and sign an agreement.
- Obtain the data related to the patients treated with the vaccine.
- When sufficient data is obtained, arrange with the collaborators to publish the results in scientific journals.

2. Search for consultancy and recommendations on how to enter clinical trials with the vaccine. Connect with companies/organizations that are willing to assist JCWO in this process, with pro bono services.

Activities:
- Search in the web for possible organizations.
• Make contact with the organizations and set up meetings to propose and arrange a collaboration agreement.

• Sign a collaboration agreement and plan the possible clinical trial phase of the vaccine.

3. Fundraise to support the free of cost immunotherapy treatment arranged with clinics, as well as all the service and research developed by our partner FJC in Venezuela.

Activities:

• Search in the web for possible organizations, which might give a donation of any kind to support JCWOs projects.

• Make contact with the organizations found and set up meetings to present JCWO projects.

• Arrange the donation process
Management Indicators for 2017

**Contacted Organizations**

- Clinics
- Consulting Organizations
- Conference, Grants and fellowships
- Fundraising & networking
- Other
- Advisors for the Committee

**Organizations that answered**

- Clinics
- Consulting Organizations
- Conference, Grants and fellowships
- Fundraising & networking
- Advisors for the Committee
ANNUAL REPORT
2014-2017

Registration in Fundraising platforms

- Number of Platforms
- Platforms raising funds

November
December
The Jacinto Convit World Organization (JCWO) is a U.S. nonprofit and non-governmental organization incorporated in 2014, that contributes primarily to important areas of public health, such as cancer and infectious diseases in developing countries.

Our story dates back to 1938 when Dr. Convit graduated from medical school and moved to the main leprosarium of Venezuela, near the capital city of Caracas. He wanted to understand the clinical, pathological, social and human aspects of the disease to alleviate the long time suffering and social exclusion of leprosy patients. For years with a team of doctors and pharmacists, he worked to find a drug that could prove that leprosy was curable and with this put an end to the compulsory isolation of patients. As he achieved this, Venezuela became the first country to close the leprosariums and start treating leprosy patients in their own communities, a model that became a world reference in the treatment of the disease.

During several decades Dr. Convit focused on the development of a vaccine to treat leprosy, based on a combination of the *Mycobacterium leprae* and BCG. His tireless work and studies on infectious diseases that affect the poorest in remote “forgotten” villages, led him a few years later to develop a vaccine to treat leishmaniasis, another devastating cutaneous disease that is endemic in tropical countries. This vaccine was based on his prior model for leprosy, using a mix of *Leishmania* with BCG. During his last years of life, Dr. Convit took upon a new challenge, cancer, as he saw in this disease an immunosuppressive behavior similar to that in leprosy and leishmaniasis, and proposed a personalized immunotherapy based on his experiences treating infectious diseases.

We promote the life, philosophy and work of Dr. Convit through specialized programs and international projects. Our main objective is to support health services that help the most underserved and underprivileged people, contributing to specific areas of public health, such as cancer and infectious diseases.
To guarantee and oversee the activities of JCWO, there are authorities who founded the NGO and/or are appointed to look after the organization. These are integrated by a multidisciplinary group of professionals that act as President and Directors of the Board.

**Founder and President**

Ana Federica Convit, MSc.

Completed her undergraduate studies at Dickinson College, Pennsylvania. She was employed in the Hong Kong Shanghai Banking Corporation in New York for eight years, in the areas of Private Banking and Foreign Exchange for institutional clients such as the central banks of several Latin American countries. Her commitment to Venezuela and her dedication to the work of her grandfather, Dr. Jacinto Convit, led her back to her country to engage in public service and work with her grandfather. In 2010 she founded the Civil Association for the Development of Cancer Immunotherapy to finance Dr. Convit's research on his autovaccine for this disease. At the same time, she obtained a Master's degree in Public Management at IESA. In 2012 she established the Jacinto Convit Foundation, which is responsible for preserving her grandfather's legacy, in addition to promoting and expanding his research and social projects. In 2015 she received the distinction as one of the 50 most influential alumni of IESA. In 2016 she inaugurated the Foundation's headquarters, a non-profit Scientific Research Center that is at the service of public health, a project that was completed based on donations from all sectors of society, mainly local and multinational companies. To date, Ana Federica is author of two publications in peer reviewed journals in the area of cancer immunotherapy.

**Board of Directors**

The board of directors is integrated by a group of highly experienced professionals from different areas, who come together to give professional advice and regulate the planned activities of the organization. As part of their duty, every project, any publication, and any activity in which JCWO is engaged goes through them for edition. The board is legally, financially, and morally responsible for the organization,
recognizing that it is entrusted with resources devoted to charitable purposes. This year the Board members met online on May 11, 2018 to review and approve several documents and agreements as indicated in the Board Consent issued on the same date. The Directors are:

- Ana Federica Convit, MSc.
- Antonio Convit, MD.
- Rafael Convit, MD.
- Lilia Correa, MD.
- Mauricio Aranguren

Ana Federica Convit, MSc.
(See profile description above)

Antonio Convit, MD.
NYU Langone Health
Professor, Department of Psychiatry/ Medicine/ Radiology

Obtained his Medical Degree from the University of Chicago, Pritzker School of Medicine and trained in Psychiatry at the New York University School of Medicine. He is a tenured Professor of Psychiatry, Medicine, and Radiology at the NYU School of Medicine in New York City. He has been involved in research and teaching for the last 30 years and has published over 140 scientific articles. Dr. Convit’s work has been at the leading edge of our understanding of how the brain is affected by obesity and diabetes and his contributions in this area were some of the very first reports in the literature. He is also the Deputy Director of the Nathan Kline Institute (NKI) and on the Board Committee for the Sackler Institute of Nutrition Science at the New York Academy of Sciences.

Rafael Convit, MD.
MedStar Health

Dr. Convit obtained his Medical Degree from the George Washington University in Washington DC. He furthered his training in General Surgery at Medstar Washington Hospital Center followed by
ANNUAL REPORT 2018

February, 2019

Plastic Surgery training at Medstar Georgetown University Hospital. His work is focused on breast cancer reconstruction in a multidisciplinary team at The Cancer Institute of Medstar Washington Hospital Center, where he uses a holistic approach to treat his patients. He also treats patients with aesthetic concerns improving their quality of life. For many years, Dr. Convit has also run a multidisciplinary clinic that caters to spinal cord injury patients with complex wounds at Medstar National Rehabilitation Hospital. He has leadership roles at the hospitals where he practices and is on the Board of Directors of Medstar National Rehabilitation Hospital.

Lilia Correa, MD.
Morristown Medical Center in Morristown
Dermatologist

 Obtained her Medical Degree at Universidad Central de Venezuela and afterwards became specialized in Dermatology. She is a board certified internist and dermatologist; also completed fellowships in Procedural Dermatology and Dermatologic Oncology. After medical school, Dr. Correa spent a year as a physician in a remote underserved area of South America. Subsequently, she performed research at Harvard’s renowned Beth Israel Deaconess Medical Center in Boston, completed her Internal Medicine residency at Cornell New York Downtown Hospital, and performed research at Memorial Sloan Kettering Cancer Center in New York. Dr. Correa completed her dermatology residency at Rutgers University while earning a number of awards and co-authoring publications and presentations. Then, completed a Mohs and Dermatologic Oncology fellowship in Affiliated Dermatologists and Dermatologic Surgeons at the Morristown Medical Center in Morristown, NJ. In addition to general dermatology, Dr. Correa also has experience in confocal microscopy and has performed multiple clinical trials involving laser related treatment, cosmeticals and body contouring.

Mauricio Aranguren
Executive Director - UBS AG Wealth Management Americas

Obtained his Bachelor’s degree with honors from Albright College in Business Administration. Since
then, he joined UBS Wealth Management for the Americas. He is currently Executive Director and a licensed client adviser that provides advice to families and related institutions. He has covered Latin America from New York, Geneva and Switzerland. Mr. Aranguren has been recognized as a Top Producer within his region for several years. He is a member of the Chairman’s Council 2018, and previously a member of the Presidents Council 2017. He was also named a council member for the Wealth Management International Advisory Committee for the 2016-2017 period.

Our Work

JCWO is focused on two main programs, Cancer Immunotherapy (CI) and Molecular Diagnostics (MD). The CI program currently develops a personalized breast cancer therapeutic vaccine, named ConvitVax, designed by Dr. Jacinto Convit during his last years of life. Previous preclinical studies and a small human experience, showed this therapy to be potentially safe and effective, as well as possibly establishing immune system memory. ConvitVax is targeted to underprivileged patients who have very little or no access to new cancer treatments and in some cases to standard of care treatments.

The MD program supports the development and expansion of a personalized, precise and free of cost diagnostic service for various types of cancers and infectious diseases to benefit underprivileged and underserved patients in developing countries who do not have access to these specialized tests. The purpose of this program is to contribute to a better healthcare system, where health conditions are highly deficient. The MD program performs a unique service in the Latin American region that provides molecular based diagnostics for children and adults in poverty and extreme poverty.

Our philosophy is based on Dr. Convit’s ideals and humanistic approach to develop treatments that can be accessible for underprivileged patients, especially in poorer countries. We believe that a society is stronger when all its people have access to a good healthcare system, including modern diagnostics and adequate treatments. This is why it is a priority for us to assist those that are most underserved in our communities.
Main Objectives

- Execute clinical trials using Dr. Convit’s immunotherapy, ConvitVax, with the aim of making this treatment available to patients who cannot access new innovative therapies and sometimes even conventional treatments.
- Build collaborative networks with international organizations, hospitals and academia to perform clinical trials and scientific research.
- Support the expansion of a cost-free molecular diagnostic service for cancer, in the Latin-American region.
- Create social impact in developing countries by giving access to cancer-related health services and treatments to underprivileged patients, especially in places where public health conditions are highly deficient.
- Serve as a platform to preserve, promote and continue Dr. Convit’s legacy through scientific and educational programs.

Allies

As strong believers in the power of teamwork over individual efforts, we are happy to say that we have made many collaborative alliances since the beginning of our journey. We hereby present our main allies.

DLA Piper

DLA Piper is a multinational law firm, regarded as one of the largest and most prestigious law firms in the world, located in more than 40 countries throughout the Americas, Asia Pacific, Europe, Africa, and the Middle East. Their office in Palo Alto is who directly assists JCWO with corporate legal matters and who incorporated our NGO in the US in 2014 as a public charity under the laws of California. Ever since they have supported us with their pro-bono services. We met with them in October of this year and they reaffirmed their commitment to continue serving JCWO.
Baker McKenzie

Baker McKenzie is the world’s strongest law firm with functional outsourcing operations, located all over the world. Corporate Social Responsibility is an integral part of their work, aiming to make a lasting difference to many of today’s social and economic challenges. Their highly specialized and qualified team has been a key support to JCWO with their legal advice, mainly in the area of intellectual property, as a pro-bono service to our NGO. Baker assisted, assessed and completed the Patent Cooperation Treaty (PCT) application to protect the intellectual property of Dr. Convit’s therapeutic vaccine, named ConvitVax. They continue to support us as we are now in the national phase of the patent process.

Camero & Company CPA, PA.

Camero & Company is a CPA firm specializing in international and national corporate solutions, including superior tax, accounting, business, and attestation services. They support JCWO with top services in accounting, tax filings and other federal and state requirements of the organization. They continue to be committed to our cause for the upcoming year.

Microsoft

The American multinational technology company, Microsoft Corporation (MS), became in 2016 a donor of Fundación Jacinto Convit (FJC) of free unlimited access to Office 365 Business. As part of the agreement between FJC and JCWO, and because both organizations share the same domain, this benefit applies also to JCWO. The Office 365 began to be widely used in 2018 by both organizations and as part of the process, all email data and documentation were transferred from Gmail to Microsoft Outlook.

Fundraising and Transparency Platforms

We present all digital platforms in which JCWO is registered, as a process to gain recognition and donations from the general public.
AmazonSmile

AmazonSmile is a website operated by Amazon with the same products, prices, and shopping features as Amazon.com, but with the specific feature that when people shop on AmazonSmile, they select one of the registered non-profits, and AmazonSmile donates 0.5% of the purchase price of eligible products to the selected charitable organization. JCWO was registered in AmazonSmile in December 2017 and since then some monetary funds have been raised, although very small amounts. For specific data see the Appendix 1.

Ebay for Charity

The program is called eBay Giving Works, in which two different fundraising approaches are offered to nonprofits, direct sales of auction items by the nonprofit group or through Community Selling. In Community Selling, an eBay seller may donate a portion of the auction proceeds to a specific nonprofit organization. By charity direct seller, a registered charity can sell their own items on eBay and collect 100% of their final sale price. In general, with eBay for Charity people can support their favorite charities when selling and buying items on eBay. Through this platform JCWO has not yet received any donation or performed a direct sale, but it is important to have this option available already.

PayPal Giving Fund

PayPal Giving Fund is an independent charitable organization that provides companies, such as PayPal, eBay, and Humble Bundle, with a secure and easy way for their customers to support their favorite causes. PayPal Giving Fund is based in three main activities: 1) Ensuring that 100% of every donation reaches the donor's chosen charity; ii) Confirming that participating charities are tax-deductible and meet international standards restricting hate, violence, and intolerance; and iii) Managing the tax benefits of giving. All donations made to charity go directly into the organization’s PayPal account for easy access and tracking, also accepting credit card payments. Through this platform JCWO obtained a direct Donate button that was added to our website, and it could also be added to any blog or our emails. Until the moment no donation has been registered through this platform, however our PayPal account has been used for pending payments.
ANNUAL REPORT 2018
February, 2019

GuideStar

GuideStar USA, Inc. is an information service specializing in reporting on U.S. nonprofit companies, it was one of the first central sources of information on U.S. nonprofits and is the world's largest source of information about nonprofit organizations. GuideStar also serves to verify that a recipient organization is established and that donated funds go where the donor intended. The GuideStar Nonprofit Profiles have implemented seals based on the information that a nonprofit provides in its profile: Bronze, Silver, and Gold; and a more recent one, Platinum, which allows nonprofits to share progress and results of their mission. JCWO has reached the Gold transparency seal in 2018.

Network for Good

Network for Good is a Certified B Corporation software company that offers innovative, easy-to-use fundraising software and coaching for charities and non-profit organizations. It is a hybrid organization, as it is a nonprofit-owned for-profit. Their nonprofit donor-advised fund uses the Internet and mobile technology to securely and efficiently distribute thousands of donations from donors to their favorite charities each year. There are some fees involved, as they charge between 3% to 5% transaction processing fee for donations, in addition to any subscription fees that the charity might incur. Transaction processing costs may be covered by the donor or by the nonprofit organization.

Network for Good provide nonprofits, corporations, and software developers with simple solutions to power the good they do with supporters, employees, and consumers. For nonprofits, they offer a suite of fundraising software and services that helps raise money and reach more individual donors. For companies, they can enable employees or customers to give to any charity on their site, social networks, and mobile devices. For software developers, through their platform they can process, track, and distribute donations to any charity. For donors, they make it easy for people to support their favorite charities, where they can choose from over 1 million of them. In 2018, some funds were received through this platform. More details can be found in the Appendix 1.
Tech Soup
TechSoup was founded as CompuMentor and later known as TechSoup Global, which is a nonprofit international network of non-governmental organizations (NGOs) that provides technical support and technological tools to other nonprofits. The registration in this platform was performed as part of the requirements to make a registration in Google for Non-profits. Their services have not been fully used.

Google for Nonprofits
Google for Nonprofits provides free tools to nonprofit organizations, in order to allow them to work more quickly and efficiently reach a wider audience, spur more supporters to take action, and tell their story in a more compelling way. Some of the benefits or access given to the registered non-profits are the use of Google tools like G Suite, Google Ads, Google Analytics, YouTube Nonprofits, Google Earth Outreach, Google+ Hangout, and Google One Today. Since JCWO’s registration, some of the benefits have been used for a better and easy search of the organization through the Google search tool. Additionally, through the Google analytics tool, our team has been able to register the internet traffic of our website.

CrowdRise
CrowdRise is a for-profit crowdfunding platform that raises charitable donations, and it was acquired in 2017 by GoFundMe. CrowdRise is based upon the notion of making giving back fun, leading to more people donating and more funds being raised. The platform uses gamification and a rewards point system to engage users to participate in fundraising and donating. It is considered the world’s largest and fastest growing fundraising platform dedicated exclusively to charitable giving, and is used by millions of individuals to raise money for their favorite charities and causes. Their default "Starter" pricing is to charge the non-profit a 5% platform fee from each donation, plus a payment processing fee (credit card fee) of 2.9% + $0.30 per donation. Donors may choose whether to pay the fee in addition to the amount of their donation or to have the fee subtracted from their donation amount before being delivered. Until now JCWO has not engaged in any crowdfunding campaign, but the option is already available for us at any time.
Great NonProfits

GreatNonprofits is a 501(c)-3 registered non-profit organization based in the U.S. that describes itself as "the leading developer of tools that allow people to find, review, and share information about great – and perhaps not yet great – nonprofits". Through their website, donors, volunteers, and clients can share their personal experiences with specific charitable organizations, as well as give reviews of these organizations, providing crowdsourced information about their reputability. In 2018 JCWO received two (2) reviews in its profile. For the upcoming year some improvements will be made to the profile, as well as more advertising of the platform, in order to obtain more reviews in 2019.

WePay

WePay is an online payment service provider based in the U.S. that provides an integrated and customizable payment solution through its Application Program Interface - APIs directed to platform businesses such as crowdfunding sites, marketplaces and small business software companies. Through its service they offer their partners fraud and risk protection. JCWO was registered in this platform as a prerequisite for the Crowdrise registration.

Wikidata

Wikidata is a collaboratively edited knowledge base hosted by the Wikimedia Foundation. It is a common source of open data that Wikimedia projects such as Wikipedia can use, and by anyone else, under a public domain license. It can be read and edited by both humans and machines, and it acts as central storage for the structured data of its Wikimedia sister projects including Wikipedia, Wikivoyage, Wikisource, and others. The content of Wikidata is available under a free license, exported using standard formats, and can be interlinked to other open data sets on the linked data web.
DonorBox

DonorBox is a powerful fundraising software that is super simple to setup and it attracts more recurring donors. Through this platform JCWO can obtain direct donations from people around the world. Until now, no donation has been received.

Stripe

Stripe is a technology company known as software platform for running an internet business. Its software allows individuals and businesses to receive payments over the Internet, as they provide the technical, fraud prevention, and banking infrastructure required to operate on-line payment systems. Stripe builds powerful and flexible tools for internet commerce, and their meticulously designed Application Program Interface - APIs and unmatched functionality help organizations create the best possible product for their users.

Charity Navigator

Charity Navigator is a major charity assessment organization that evaluates non-profits in the U.S., and it operates as a free 501(c)(3) organization that accepts no advertising or donations from the organizations it evaluates. It was created as an unbiased source of information that could provide charitable givers and social investors across the country with every type of charitable interest, helping donors to make informed giving decisions and enabling well-run charities to demonstrate their commitment to proper stewardship. JCWO has a profile on the Charity Navigator page, which ensures that the potential donors visiting its profile have accurate and clear data to guide their giving decisions, giving some prestigious to the organization and also increasing he probabilities of receiving donations.

Donors

JCWO is a true example of a combined effort by multiple institutions and individuals that strongly believe in the necessity of making this project a reality, and with their support we are able to achieve our goal to give access to better healthcare solutions to those who need it the most. In this path we have
received from different sources, multiple donations in liquid funds and also as pro bono services. The specifics on all donations received during this year are presented in Appendix 1.

Fundasitio

Fundasitio is a non-profit organization dedicated to promote the diffusion of charitable organizations by creating and donating websites. They began to work with us in 2017 and in 2018 JCWO we launched our web page, under a donation agreement signed with them. After many interactions, corrections, and exchange of ideas, JCWO’s web page was released early 2018, with a very interactive page and also with an available mobile version.

Chevron Corporation

Chevron Corporation is an American multinational energy corporation, one of the successor companies of Standard Oil active in more than 180 countries, being one of the world's largest oil companies. The company’s operations are accompanied by social investment programs that support economic development, education and health initiatives to strengthen the communities in the areas where they work. Chevron participates in five onshore and offshore production projects in Venezuela, a legacy that dates back to the 1920s. As part of Chevron’s social investment strategy in the communities, and within the economic development area and business innovation, they presented the “Award for Women Entrepreneurs” last year in 2017 to our sister organization FJC, which was then granted to Jacinto Convit World Organization, to support the expenses of the molecular diagnostics program. This Award pertains to a special program called the Ideas Contest, a competition that recognizes innovative ideas. The specifications on all received donations during this year are presented in Appendix 1.

I Love Venezuela Foundation

I Love Venezuela Foundation is a non-profit organization founded by a group of committed Venezuelan citizens that are interested in assisting established NGO’s in Venezuela, to help them fulfill their objectives by supporting them with necessary resources. This year the MD was benefitted by this organization to acquire the necessary reagents to continue performing tests for cancer and HIV patients.
JCWO received this donation on behalf of FJC and purchased the required material and supplies in the US for the maintenance of the MD program. This donation benefited all the pediatric patients that were evaluated and treated in public hospitals in Venezuela with whom FJC has a cooperating agreement. The specifications on all received donations during this year are presented in Appendix 1.

Fundraising Platforms
As mentioned previously in Our Allies, JCWO is registered in several platforms that help to raise funds in an easy way for both the donor and the NGO. This year we started to receive some funds through Amazon Smile and Network for Goods. More detailed information on the donations received during this year are presented in Appendix 1.

Achievements
JCWO’s team
Only one year ago JCWO started conforming its staff, when a dream became a reality and JCWO began building international efforts, collaborative networks and advancing in the clinical project for the use of the ConvitVax as a breast cancer treatment. During 2018 we have built a highly qualified, committed and multidisciplinary team, from our Board of Directors to our staff and collaborators. After incorporating JCWO and setting up its structure, the team began efforts to build international networks and alliances to advance in the clinical project for the development of the ConvitVax as a breast cancer treatment. Furthermore the organization advanced in the launching of its webpage, released in early 2018. A main support for all this work and effort has been JCWO’s Board of Directors, who have looked after all of its activities.

Research team
As part of JCWO’s achievements is the conformation of its scientific team, which began in 2017. The following are the main researchers:
Eglys González, PhD.

Obtained her Bachelor’s degree in Bioanalysis from the University of Carabobo in Venezuela and her Doctorate in Microbiology from the Venezuelan Institute of Scientific Research (Instituto Venezolano de Investigaciones Científicas – IVIC). During her PhD studies and subsequent Post-doctoral work she worked with Trypanosomatid parasites, specifically with *T. cruzi* and *Leishmania spp.* in vitro and in vivo in murine model. Dr. González was the Research Coordinator of Fundación Jacinto Convit, during the years 2013-2015, participating in the planning of the FJC’s headquarter, and then became a scientific adviser to the Foundation.

Her past experiences include working in the Laboratory of Parasite Physiology at the Center of Biophysics and Biochemistry at IVIC, and the Laboratory of Parasite Enzymology at the University of Los Andes, both located in Venezuela. She was a fellow of the Center for Advanced Studies at IVIC, and FONACIT (National Fund for Science, Technology and Innovation) in the area of agricultural technology. Dr. González is specialized in Biochemistry and Molecular Parasitology, with various related publications. In the recent years she has gained experience in cancer immunotherapy focusing on Dr. Convit’s cancer vaccine, with one peer reviewed article. Today leads the international efforts as the International Representative of the Jacinto Convit World Organization based in Germany. She is responsible for the international approach for networking, project development and social network management. Also working in the constitution of the institutional bases of JCWO to keep evolving as a non-profit organization.

María José Godoy, PhD.

Obtained her undergraduate degree in Bioanalysis from Universidad Central de Venezuela and her PhD in Biological Science at Universidad Simon Bolívar, with honors. Her awarded thesis was on molecular analysis of the main myeloid acute leukemias, and detection of several genes associated with the response to treatments. She became the Research Coordinator of Fundación Jacinto Convit during the years 2015-2017. Since then she has been a Research Collaborator for the Jacinto Convit World
Organization, and author of peer reviewed publications to continue Dr. Convit’s work in cancer immunotherapy.

Her past experiences include working in the Cellular Biology Laboratory at Universidad Simon Bolivar. Dr. Godoy has participated in several trainings and scientific symposiums in several countries and has an international certification in molecular biology from the American Society for Clinical Pathology. She is currently a postdoctoral research associate at the University of Illinois in Chicago. As a collaborator she contributes with the continuing of the development of Dr. Convits Immunotherapy, publishing scientific articles and advising the scientific team regarding the ongoing scientific programs.

Jeismar Carballo, PhD.
Obtained her Bachelor’s degree in Biology from Universidad Central de Venezuela, and received an honorable mention for her thesis. Completed her PhD in Biological Science at Universidad Simón Bolívar in Venezuela, with honors in her doctoral thesis. During her doctoral studies, her research was focused on: “The effect of the factors released by the peripheral nerves of rat, in the differentiation of neuronal cells and the regeneration of sciatic nerves of rats” and “The neuroprotective effect of Neuregulin-1 in mice, after an ischemic stroke”. Dr. Carballo was Researcher III in Fundación Jacinto Convit during 2018.

Her past experiences include working as a researcher in the Neurosciences Unit of Instituto de Estudios Avanzados, for 8 years, focused on the process of regeneration of the nervous system. Dr. Carballo obtained a scholarship from the German Academic Exchange Service (DAAD) for one (1) year, to carry out part of a research project at the Essen University Hospital-Germany, on the evaluation of drugs after an ischemic stroke. She has participated in several trainings and scientific events, both national and international. She is main author of various publications in indexed journals. Today holds the position of Scientific Officer in Jacinto Convit World Organization Inc. She is responsible for supporting in the international networking efforts, bringing the clinical project of the ConvitVax into
many hospitals around the world. As well she supports with the fundraising efforts and the search of institutional alliances.

The ConvitVax in clinical trials
As part of JCWO’s objectives, a significant effort was made to prepare an IND application to request approval from the FDA to begin phase I clinical trials with ConvitVax for the treatment of stage IV breast cancer patients. The initial submission was made on September 5th 2018 and after many interactions with FDA Officers and significant improvements made to the application under strict deadlines, on November 16th the FDA sent the final approval to begin clinical trials in Venezuela. JCWO is proud to say that an intensive team effort led us to the success in this application.

Scientific publications
After the pre-clinical studies and data analysis for the testing of the ConvitVax in a breast cancer murine model, in April 2018 JCWO published the results in an international peer-reviewed journal, Oncotarget. The article is titled “Autologous tumor cells/bacillus Calmette-Guérin/formalin-based novel breast cancer vaccine induces an immune antitumor response”. Further efforts are being made to publish the results of the combination of the ConvitVax with anti-PD1 in a breast cancer murine model.

Scientific conferences
The results of the pre-clinical study evaluating the antitumor effect of the ConvitVax in combination with anti-PD1, were presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival (CICON18). JCWO’s President Ana Federica Convit together with Dr. Maria José Godoy and Dr. Eglys González traveled to New York City on October 2018 and presented this scientific work. Additionally, the team dedicated an important amount of time to networking efforts, meeting with international renowned researchers in cancer and building relationships. The participation in such an illustrious conference is a significant milestone achieved by JCWO’s team, as a result of a visionary strategy, hard work and team effort.
Social Networks Activity

At the beginning of 2018 JCWO started the management of social networks such as Twitter, LinkedIn, Instagram and Facebook. Publications were made every day about our work and information of interest, increasing continuously the number of followers and interactions within the networks.

As part of these efforts, during 2018 JCWO was registered in many fundraising and networking platforms, completing the organization’s profile in each and beginning to raise some funds. With the registration in AmazonSmile, JCWO has gained some recognition and a small amount of funds. As well as in Network for Good, through which JCWO has obtained a more substantial donation. Additionally, with the registration on Guidestar and the publication of institutional non-confidential data, JCWO gained the 2018 Gold Transparency Seal. The use of these and many other platforms has signified the recognition of the organization and getting the public to know JCWO’s goals and efforts.

Patent

A patent is a form of intellectual property that gives its owner the right to exclude others from making, using, selling, and importing an invention for a limited period of time, usually twenty years. Based on Dr. Convit’s work and our institutional philosophy, all our services are free of cost for the patients, in order to benefit the most underprivileged population around the world. Therefore, in an effort to protect the legacy of Dr. Convit and making sure that his inventions are of free access, JCWO patented the cancer vaccine formulation, titled "AN IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER AND METHODS OF PREPARING THE SAME" under the number 10092451- 50214648-0000.

The protection of the invention was initiated in Venezuela by FJC on May 10th 2016, then the International application published under the Patent Cooperation Treaty was filed by JCWO in November 16th 2017. As the law indicates, one year after JCWO had to decide the countries in which the protection should be filed, and since November 2018 the Patent Cooperation Treaty application was introduced in the US, Brazil, Colombia, Chile and Europe. The specific dates are as follows: November 9th in Brazil, November 1st in the US, December 10th in Europe, December 14th in Colombia and December 28th in Chile.
The JCWO's 2018 financial information

<table>
<thead>
<tr>
<th>ITEMS</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
</tr>
<tr>
<td>Contributions, gifts, grants, and similar amounts received</td>
<td>14,339,00</td>
</tr>
<tr>
<td>Investment income</td>
<td>467,00</td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td>14,806,00</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
</tr>
<tr>
<td>Salaries, other compensation, and employee benefits</td>
<td>4,791,00</td>
</tr>
<tr>
<td>Professional fees and other payments to independent contractors</td>
<td>11,200,00</td>
</tr>
<tr>
<td>Printing, publications, postage, and shipping</td>
<td>3,400,00</td>
</tr>
<tr>
<td>Other expenses</td>
<td>13,468,00</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>32,859,00</td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td></td>
</tr>
<tr>
<td>Excess or (deficit) for the year</td>
<td>18,053,00</td>
</tr>
<tr>
<td>Net assets or fund balances at beginning of year</td>
<td>182,343,00</td>
</tr>
<tr>
<td>Net assets or fund balances at end of year</td>
<td>164,290,00</td>
</tr>
</tbody>
</table>
Appendix 1. Donations received

<table>
<thead>
<tr>
<th>Institution</th>
<th>Date</th>
<th>Type of donation</th>
<th>Amount ($)</th>
<th>Purpose of the donation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundasitio</td>
<td>N/A</td>
<td>Service</td>
<td>N/A</td>
<td>Web page</td>
</tr>
<tr>
<td>Microsoft</td>
<td>N/A</td>
<td>Service</td>
<td>N/A</td>
<td>Office 365 Business License</td>
</tr>
<tr>
<td>Chevron</td>
<td></td>
<td>Monetary</td>
<td>8,000.00</td>
<td>Molecular Diagnostics Program</td>
</tr>
<tr>
<td>I Love Venezuela</td>
<td></td>
<td>Monetary</td>
<td>6,000.00</td>
<td>Molecular Diagnostics Program</td>
</tr>
<tr>
<td>Amazon Smile</td>
<td>Accumulative during the year</td>
<td>Monetary</td>
<td>29,73</td>
<td>General</td>
</tr>
<tr>
<td>Network for Good</td>
<td>Accumulative during the year</td>
<td>Monetary</td>
<td>310,00</td>
<td>General</td>
</tr>
</tbody>
</table>
## ESTIMATED BUDGET FOR JCWO 2019

<table>
<thead>
<tr>
<th>ITEMS</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Estimated Revenue</strong></td>
<td></td>
</tr>
<tr>
<td>Private organizations</td>
<td>40,000,00</td>
</tr>
<tr>
<td>Foreign government</td>
<td>70,000,00</td>
</tr>
<tr>
<td>Fundraising Platforms</td>
<td>500,00</td>
</tr>
<tr>
<td>Individual Contributions</td>
<td>100,00</td>
</tr>
<tr>
<td><strong>Total Projected Income</strong></td>
<td><strong>110,600,00</strong></td>
</tr>
<tr>
<td><strong>Estimated Expenses</strong></td>
<td></td>
</tr>
<tr>
<td>Molecular Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Reagents</td>
<td>5,000,00</td>
</tr>
<tr>
<td>Supplies</td>
<td>2,000,00</td>
</tr>
<tr>
<td>Equipment</td>
<td>65,000,00</td>
</tr>
<tr>
<td>Cancer Immunotherapy</td>
<td></td>
</tr>
<tr>
<td>Reagents</td>
<td>1,000,00</td>
</tr>
<tr>
<td>Supplies</td>
<td>500,00</td>
</tr>
<tr>
<td><strong>Fundraising Component</strong></td>
<td></td>
</tr>
<tr>
<td>Personnel</td>
<td>7,000,00</td>
</tr>
<tr>
<td>Others (phone, office material, among others)</td>
<td>4,000,00</td>
</tr>
<tr>
<td><strong>Administrative</strong></td>
<td></td>
</tr>
<tr>
<td>Personnel</td>
<td>23,000,00</td>
</tr>
<tr>
<td>Others</td>
<td>3,100,00</td>
</tr>
<tr>
<td><strong>Total Estimated Expenses</strong></td>
<td><strong>110,600,00</strong></td>
</tr>
</tbody>
</table>
Specific objectives and activities

1. Arrange collaboration agreements with health and research centers, academia, NGOs or any institution that may serve for the purposes of JCWO, keeping up to date the database of institutions to be contacted.

Activities:
- Follow up through e-mail and phone to purge the database.
- Contact and keep up conversations with all previous included institutions and determine whether they are interested in collaborating or not, to purge the list.
- Identify new institutions to be included in the database, define what kind of relation can offer JCWO, identify the appropriate contact person to speak with, and make a first contact with them.
- Send the adequate proposal to the institutions, make a constant follow up of the requests sent, and when interested give all information related to a collaborative relationship with them.
- If a positive response is given to our collaborative request, then arrange all related to the setting up of an agreement.

2. Inclusion of the vaccine into clinical trials.

Activities:
- Keep up with the consultations with appropriate institutions to make sure the vaccine can go into clinical trial and obtain information related to the requirements to include the vaccine in clinical trial.
- Continue to improve the clinical protocol of the vaccine, including generating a patient consent approved by the corresponding lawyers.
- Maintain the communication with the institutions previously contacted for partnering in performing a clinical trial with JCWO, including any improvements to be made to the clinical protocol and generating a proper clinical project.

- Find new cooperative institutions with whom JCWO can partner for performing a clinical trial inside and outside the US.

- Continue trying to obtain a pro-bono or partial pro-bono service from the organizations that might help in the process of starting and performing a clinical trial.

3. Raising funds to support the free of cost immunotherapy treatment offered, as well as all the services for the molecular diagnostics program.

Activities:
- Continue to feed the list of organization to contact for donation requests, following up the status of those requests already sent.
- Develop a proper project to register within the organizations that give grants for research or clinical studies.
- If any agreement for clinical trial is achieved, make all related efforts to raise funds for this purpose.
- Continue to register JCWO in new fundraising and networking digital platforms.
- From the platforms already in use, identify all services useful for JCWO’s interests and perform all processes required for an optimal use of these tools. This is to be performed also for any new platform included.
- Arrange donation agreements.

4. Support all related activities with the media for JCWO.

Activities:
- Feed up the new launched web page with appropriate information and content of interest.
- Give support in the process of feeding the social networks of JCWO.
Management Indicators for 2018

Contacted Organizations

- Clinics
- Consulting Organizations
- Conference, Grants and fellowships
- Fundraising & networking
- Other
- Advisors for the Committee

Organizations that answered

- Clinics
- Consulting Organizations
- Conference, Grants and fellowships
- Fundraising & networking
- Advisors for the Committee
The Jacinto Convit World Organization (JCWO) is a U.S. nonprofit and non-governmental organization incorporated in 2014 that contributes primarily to important areas of public health, such as cancer and infectious diseases in developing countries.

Our story dates back to 1938 when Dr. Convit graduated from medical school and moved to the main leprosarium of Venezuela, near the capital city of Caracas. He wanted to understand the clinical, pathological, social and human aspects of the disease to alleviate the long time suffering and social exclusion of leprosy patients. For years with a team of doctors and pharmacists, he worked to find a drug that could prove that leprosy was curable and with this put an end to the compulsory isolation of patients. As he achieved this, Venezuela became the first country to close the leprosariums and start treating leprosy patients in their own communities, a model that became a world reference in the treatment of the disease.

During several decades Dr. Convit focused on the development of a vaccine to treat leprosy, based on a combination of the *Mycobacterium leprae* and BCG. His tireless work and studies on infectious diseases that affect the poorest in remote “forgotten” villages, led him a few years later to develop a vaccine to treat leishmaniasis, another devastating cutaneous disease that is endemic in tropical countries. This vaccine was based on his prior model for leprosy, using a mix of *Leishmania* with BCG. During his last years of life, Dr. Convit took upon a new challenge, cancer, as he saw in this disease an immunosuppressive behavior similar to that in leprosy and leishmaniasis, and proposed a personalized immunotherapy based on his experiences treating infectious diseases.

We promote the life, philosophy and work of Dr. Convit through specialized programs and international projects. Our main objective is to support health services that help the most underserved and underprivileged people, contributing to specific areas of public health, such as cancer and infectious diseases.
To guarantee and oversee the activities of JCWO, there are authorities who founded the NGO and/or are appointed to look after the organization. These are integrated by a multidisciplinary group of professionals that act as President and Directors of the Board.

**Founder and President**

Ana Federica Convit, MSc.

Completed her undergraduate studies at Dickinson College, Pennsylvania. She was employed in the Hong Kong Shanghai Banking Corporation in New York for eight years, in the areas of Private Banking and Foreign Exchange for institutional clients such as the central banks of several Latin American countries. Her commitment to Venezuela and her dedication to the work of her grandfather, Dr. Jacinto Convit, led her back to her country to engage in public service and work with her grandfather. In 2010 she founded the Civil Association for the Development of Cancer Immunotherapy to finance Dr. Convit's research on his autovaccine for this disease. At the same time, she obtained a Master’s degree in Public Management at IESA. In 2012 she established the Jacinto Convit Foundation, which is responsible for preserving her grandfather's legacy, in addition to promoting and expanding his research and social projects. In 2015 she received the distinction as one of the 50 most influential alumni of IESA. In 2016 she inaugurated the Foundation's headquarters, a non-profit Scientific Research Center that is at the service of public health, a project that was completed based on donations from all sectors of society, mainly local and multinational companies. To date, Ana Federica is author of three publications in peer reviewed journals in the area of cancer immunotherapy.

**Board of Directors**

The board of directors is integrated by a group of highly experienced professionals from different areas, who come together to give professional advice and regulate the planned activities of the organization. As part of their duty, every project, any publication, and any activity in which JCWO is engaged goes through them for edition. The board is legally, financially, and morally responsible for the organization,
recognizing that it is entrusted with resources devoted to charitable purposes and expected to protect their interests.

This year the Board members met online on January 30, 2019 to review and approve several documents and agreements as indicated in the Board Consent issued on the same date. The Directors are:

- Ana Federica Convit, MSc.
- Antonio Convit, MD.
- Rafael Convit, MD.
- Lilia Correa, MD.
- Mauricio Aranguren

Ana Federica Convit, MSc.
(See profile description above)

Antonio Convit, MD.
NYU Langone Health
Professor, Department of Psychiatry/ Medicine/ Radiology

Obtained his Medical Degree from the University of Chicago, Pritzker School of Medicine and trained in Psychiatry at the New York University School of Medicine. He is a tenured Professor of Psychiatry, Medicine, and Radiology at the NYU School of Medicine in New York City. He has been involved in research and teaching for the last 30 years and has published over 140 scientific articles. Dr. Convit’s work has been at the leading edge of our understanding of how the brain is affected by obesity and diabetes and his contributions in this area were some of the very first reports in the literature. He is also the Deputy Director of the Nathan Kline Institute (NKI) and on the Board Committee for the Sackler Institute of Nutrition Science at the New York Academy of Sciences.

Rafael Convit, MD.
MedStar Health
Dr. Convit obtained his Medical Degree from the George Washington University in Washington DC. He furthered his training in General Surgery at Medstar Washington Hospital Center followed by Plastic Surgery training at Medstar Georgetown University Hospital. His work is focused on breast cancer reconstruction in a multidisciplinary team at The Cancer Institute of Medstar Washington Hospital Center, where he uses a holistic approach to treat his patients. He also treats patients with aesthetic concerns improving their quality of life. For many years, Dr. Convit has also run a multidisciplinary clinic that caters to spinal cord injury patients with complex wounds at Medstar National Rehabilitation Hospital. He has leadership roles at the hospitals where he practices and is on the Board of Directors of Medstar National Rehabilitation Hospital.

Lilia Correa, MD.
Indian River Medical Center.
Director of Cutaneous Surgery at Scully Welsh Cancer Center.

Obtained her Medical Degree at Universidad Central de Venezuela and afterwards became specialized in Dermatology. She is a board certified internist and dermatologist; also completed fellowships in Procedural Dermatology and Dermatologic Oncology. After medical school, Dr. Correa spent a year as a physician in a remote underserved area of South America. Subsequently, she performed research at Harvard’s renowned Beth Israel Deaconess Medical Center in Boston, completed her Internal Medicine residency at Cornell New York Downtown Hospital, and performed research at Memorial Sloan Kettering Cancer Center in New York. Dr. Correa completed her dermatology residency at Rutgers University while earning a number of awards and co-authoring publications and presentations. Then, completed a Mohs and Dermatologic Oncology fellowship in Affiliated Dermatologists and Dermatologic Surgeons at the Morristown Medical Center in Morristown, NJ. In addition to general dermatology, Dr. Correa also has experience in confocal microscopy and has performed multiple clinical trials involving laser related treatment, cosmetics and body contouring.
Mauricio Aranguren
Executive Director - UBS AG Wealth Management Americas

Obtained his Bachelor’s degree with honors from Albright College in Business Administration. Since then, he joined UBS Wealth Management for the Americas. He is currently Executive Director and a licensed client adviser that provides advice to families and related institutions. He has covered Latin America from New York, Geneva and Switzerland. Mr. Aranguren has been recognized as a Top Producer within his region for several years. He is a member of the Chairman’s Council 2018, and previously a member of the Presidents Council 2017. He was also named a council member for the Wealth Management International Advisory Committee for the 2016-2017 period.

Our Work
JCWO is focused on two main programs, Cancer Immunotherapy (CI) and Molecular Diagnostics (MD). The CI program currently develops a personalized breast cancer therapeutic vaccine, named ConvitVax, designed by Dr. Jacinto Convit during his last years of life. Previous preclinical studies and a small human experience, showed this therapy to be potentially safe and effective, as well as possibly establishing immune system memory. ConvitVax is targeted to underprivileged patients who have very little or no access to new cancer treatments and in some cases to standard of care treatments.

The MD program supports the development and expansion of a personalized, precise and free of cost diagnostic service for various types of cancers and infectious diseases to benefit underprivileged and underserved patients in developing countries who do not have access to these specialized tests. The purpose of this program is to contribute to a better healthcare system, where health conditions are highly deficient. The MD program performs a unique service in Venezuela carried out by our sister organization Fundación Jacinto Convit (FJC) that provides molecular based diagnostics for children and adults in poverty and extreme poverty.

Our philosophy is based on Dr. Convit’s ideals and humanistic approach to develop treatments that can be accessible for underprivileged patients, especially in poorer countries. We believe that a society is
stronger when all its people have access to a good healthcare system, including modern diagnostics and adequate treatments. This is why it is a priority for us to assist those that are most underserved in our communities.

Main Objectives

- Execute clinical trials using Dr. Convit’s immunotherapy, ConvitVax, with the aim of making this treatment available to patients who cannot access new innovative therapies and sometimes even conventional treatments.
- Build collaborative networks with international organizations, hospitals and academia to perform clinical trials and scientific research.
- Support the expansion of a cost-free molecular diagnostic service for cancer, in the Latin-American region.
- Create social impact in developing countries by giving access to cancer-related health services and treatments to underprivileged patients, especially in places where public health conditions are highly deficient.
- Serve as a platform to preserve, promote and continue Dr. Convit’s legacy through scientific and educational programs.

Allies

As strong believers in the power of team work over individual efforts, we are happy to say that we have made many collaborative alliances since the beginning of our journey. We hereby present our main allies.

DLA Piper

DLA Piper is a multinational law firm, regarded as one of the largest and most prestigious law firms in the world, located in more than 40 countries throughout the Americas, Asia Pacific, Europe, Africa, and the Middle East. Their office in Palo Alto is who directly assists JCWO with corporate legal matters and who incorporated our NGO in the US in 2014 as a public charity under the laws of
California. Ever since they have supported us with their pro-bono services. They are committed to continue serving JCWO.

Baker McKenzie

Baker Mckenzie is the world’s strongest law firm with functional outsourcing operations, located all over the world. Corporate Social Responsibility is an integral part of their work, aiming to make a lasting difference to many of today’s social and economic challenges. Their highly specialized and qualified team has been a key support to JCWO with their legal advice, mainly in the area of intellectual property, as a pro-bono service to our NGO. Baker assisted, assessed and completed the Patent Cooperation Treaty (PCT) application to protect the intellectual property of Dr. Convit’s therapeutic vaccine, named ConvitVax. They continue to support us as we are now in the national phase of the patent process. During 2019, their team in Washington, DC investigated if JCWO would be sanctioned by the US government since it supports a Venezuelan organization, which is FJC. The Baker Mckenzie team concluded the following:

Executive Order 13884 ("EO 13884") that was issued on August 5, 2019 blocks all property and interests in property of the Government of Venezuela ("GOV") and generally prohibits US Persons from dealing with the GOV.

Assuming (as appears to be the case based on the information provided) that FJC is not owned or controlled by the Government of Venezuela ("GOV"), it would not be subject to the US blocking sanctions that apply to the GOV. This means that US persons are not prohibited from dealing with FJC and may continue to freely engage with FJC, including receiving USD donations and funding, equipment from US Persons, etc.

In our view, the fact that FJC has cooperation agreements in place with Venezuelan State health institutions wherein those health institutions collect medical samples from patients and deliver them to FJC for analysis would not result in FJC falling within the definition of the GOV because FJC is not acting or purporting to act directly or indirectly for any GOV entities in carrying out these activities.
Even if it did fall within the definition of the GOV, there are several general licenses ("GL") that would authorize US person involvement with FJC. Note that each of these GLs has certain terms and conditions and may require confirmation that they are all satisfied, but the below is a preliminary assessment of GLs that may apply.

Because our view is that the FJC does not meet the definition of the GOV (or otherwise falls within the scope of the one of the GLs above) and therefore is not subject to blocking sanctions, the JCWO's support (financial, equipment, and US Person board members) of the FJC would not be prohibited. In fact, the FJC's activities are precisely the type that the US Government has excluded from the scope of the sanctions targeting Venezuela.

Camero & Company CPA, PA.

Camero & Company is a CPA firm specializing in international and national corporate solutions, including superior tax, accounting, business, and attestation services. They support JCWO with top services in accounting, tax filings and other federal and state requirements of the organization. In November 2019, the president of the organization visited the facilities and shared with the Camero & Company team thanking all the support provided. Additionally, for the management of the organization's account, it was decided to close the account at The Hong Kong and Shanghai Banking Corporation (HSBC) and on November 13, 2019, the Bank of America account of JCWO was opened. This was their last year supporting the organization and we deeply appreciate all the commitment with JCWO and the great work they did to keep the accountability of the organization in order and in compliance with the IRS.

Microsoft

The American multinational technology company, Microsoft Corporation (MS), became in 2016 a donor of Fundación Jacinto Convit (FJC) of free unlimited access to Office 365 Business. As part of the agreement between FJC and JCWO, and because both organizations share the same domain, this
benefit applies also to JCWO. The Office 365 is widely used in the organization, using in addition to email all the applications it offers.

**Fundraising and Transparency Platforms**

JCWO is now validated by 16 fundraising and transparency organizations through which individuals can contribute to the development and execution of its programs. Anyone in any part of the world can access our profile through the most popular donating sites and support our work.

**AmazonSmile**

JCWO was registered in AmazonSmile in December 2017 and since then some monetary funds have been raised, although very small amounts. This year donation was received through this system, for specific data see the Appendix 1.

**Charity Navigator**

JCWO has a profile on the Charity Navigator page, which ensures that the potential donors visiting its profile have accurate and clear data to guide their giving decisions, giving some prestigious to the organization and also increasing he probabilities of receiving donations. This year no donation was received through this system.

**CrowdRise**

CrowdRise is a for-profit crowdfunding platform that raises charitable donations, and it was acquired in 2017 by GoFundMe. Donors may choose whether to pay the fee in addition to the amount of their donation or to have the fee subtracted from their donation amount before being delivered. Until now JCWO has not engaged in any crowdfunding campaign, but the option is already available for us at any time. This year no donation was received through this system.
DonorBox

DonorBox is a powerful fundraising software that is super simple to setup and it attracts more recurring donors. Through this platform JCWO can obtain direct donations from people around the world. Until now, no donation has been received.

Ebay for Charity

The people can support their favorite charities when selling and buying items on eBay. Through this platform JCWO has not yet received any donation or performed a direct sale, but it is important to have this option available already.

Fidelity Charitable

They help donors maximize their generosity through this donor-advised fund, called the Giving Account. The Giving Account streamlines the process of strategic giving for a broad range of donors, allowing them to contribute many types of assets and plan their giving more systematically. Until now, no donation has been received.

Great NonProfits

GreatNonprofits is a 501(c)-3 registered non-profit organization based in the U.S. that describes itself as "the leading developer of tools that allow people to find, review, and share information about great – and perhaps not yet great – nonprofits". Through their website, donors, volunteers, and clients can share their personal experiences with specific charitable organizations, as well as give reviews of these organizations, providing crowdsourced information about their reputability. This year no donation was received through this system.

GuideStar

GuideStar USA, Inc. is an information service specializing in reporting on U.S. nonprofit companies, it was one of the first central sources of information on U.S. nonprofits and is the world's largest source
of information about nonprofit organizations. GuideStar also serves to verify that a recipient organization is established and that donated funds go where the donor intended. The GuideStar Nonprofit Profiles have implemented seals based on the information that a nonprofit provides in its profile: Bronze, Silver, and Gold; and lastly Platinum, which allows nonprofits to share progress and results of their mission. JCWO reached the Platinum transparency seal in 2019. The seal needs to be renewed every year and posted on JCWO’s home web page.

Network for Good

Network for Good provides nonprofits, corporations, and software developers with simple solutions to power the good they do with supporters, employees, and consumers. For nonprofits, they offer a suite of fundraising software and services that helps raise money and reach more individual donors. For companies, they can enable employees or customers to give to any charity on their site, social networks, and mobile devices. For software developers, through their platform they can process, track, and distribute donations to any charity. This year no donation was received through this system.

PayPal Giving Fund

PayPal Giving Fund is an independent charitable organization that provides companies, such as PayPal, eBay, and Humble Bundle, with a secure and easy way for their customers to support their favorite causes. Through this platform JCWO obtained a direct Donate button that was added to our website, and it could also be added to any blog or our emails. Until the moment no donation has been registered through this platform, however our PayPal account has been used for pending payments.

This year the organization was registered on the following platforms to gain recognition and donations from the general public:

BBB

The Better Business Bureau (BBB), is a private, nonprofit organization whose self-described mission is to focus on advancing marketplace trust, incorporated in the United States and Canada. BBB
Accreditation Standards represent standards for business accreditation; their code represents sound advertising, selling and customer service practices that enhance customer trust and confidence in business. To obtain BBB accreditation, at the end of 2019 the application was completed and sent to BBB for evaluation. It is expected that early 2020 we will obtain the results of the accreditation.

Benevity
The Benevity Goodness Platform helps brands bring their social mission to life with technology to build a positive workplace culture, amplify the impact of corporate giving, and power pro-social brand engagement. The portal connects charities and nonprofit organizations all over the world with hundreds of corporate giving, matching and volunteering programs. This year no donation was received through this system.

Causes
Causes is the place to discover, support and organize campaigns, fundraisers, and petitions around the issues that impact you and your community. So far, the organization has not generated any campaigns but it is expected that this year it will begin a new phase to obtain funds. Until now JCWO has not engaged in any crowdfunding campaign, but the option is already available for us at any time.

GoFundme Charity
GoFundme Charity is an American for-profit crowdfunding platform that allows Charities to raise money for their cause and is the biggest crowdfunding platform, responsible for raising over $5 billion since its debut in 2010. Until now JCWO has not engaged in any crowdfunding campaign, but the option is already available for us at any time.

Just Giving
JustGiving is a global online social platform for giving. Is a one-stop-shop that enables all types of fundraising and giving. It helps the charities and their fundraisers to champion their story maximizes
the donations they can receive from a series of activities and helps build bonds between the charity and the supporters and advocates. This year no donation was received through this system.

Mighty Causes
Mightycause is a modern, all-in-one platform for nonprofit fundraising, donor management, marketing, and more. For more than twelve years, Mightycause has served as a platform for underfunded nonprofits and people in need, to lift up themselves and each other. This year no donation was received through this system.

Percent
WearePercent Provider of an online platform intended to help users in raising money for different causes. They have created an ecosystem of likeminded retailers, charities and brands to fix some of the world's biggest problems. By downloading Percent, every time someone chooses to spend with the exclusive retail partners, as a thank you, they will donate a percentage of what you spent to your favorite charity. This year no donation was received through this system.

Donors
JCWO is a true example of a combined effort by multiple institutions and individuals that strongly believe in the necessity of making this project a reality, and with their support we are able to achieve our goal to give access to better healthcare solutions to those who need it the most. In this path we have received from different sources, multiple donations in liquid funds and also as pro bono services. The specifics on all donations received during this year are presented in Appendix 1.

Government of Japan
This year the honorable Government of Japan selected the MDP to provide it with specialized laboratory equipment through its Non-Refundable Financial Assistance Program for Community Projects in developing countries. With the resources obtained, it was purchased: Fluorescence
microscope, cryostat, laminar flow hood, nitrogen tank, clamp base, thermometers. With the new equipment donated, we plan to increase the number of beneficiaries, implement more laboratory techniques, and standardize new tests in order to benefit more patients (Appendix 1).

Kalstein France
Is company with large experience in manufacturing and exporting high quality laboratory equipment, having honesty, responsibility and communication as the foundation in the development of each of our products. They are a leader company in the laboratory equipment field with a close relationship with each of its clients. This year the Organization received the donation of a bacteriological incubator to continue strengthening the scientific programs (Appendix 1).

Repsol
This corporation is one of the largest energy companies, present in the entire value chain: exploration and production, transformation, development and commercialization of efficient, sustainable and competitive energy. On this occasion the corporation donated a CO$_2$ incubator for the MDP, in which the necessary cell lines for the validation of the diagnostic protocols will be maintained (Appendix 1).

Foundation for Endemic Disease
Foundation for Endemic Disease has a mission to contribute to the relief of endemic disease in Venezuela. This foundation contributed with the aim of covering 2019 operational costs of JCWO and they are committed to the work of diagnostic work and promotion of solutions for cancer and infectious diseases in Venezuela (Appendix 1).

Fundraising Platforms
As mentioned previously in Allies, JCWO is registered in several platforms that help to raise funds in an easy way for both the donor and the NGO. This year we received some funds through Amazon Smile. More detailed on the donations received during this year are presented in Appendix 1.
Achievements

JCWO’s team

At the end of 2017 JCWO started conforming its staff, when a dream became a reality and JCWO began building international efforts, collaborative networks and advancing in the clinical project for the use of the ConvitVax as a breast cancer treatment. During 2019 we have built a highly qualified, committed and multidisciplinary team, from our staff to collaborators and specialists. After incorporating JCWO and setting up its structure, the team began efforts to build international networks and alliances to advance in the clinical project for the development of the ConvitVax as a breast cancer treatment. JCWO believes in the power of team work over individual efforts and the importance of a multidisciplinary team. We are thrilled to say that during 2019 we brought in new team members who potentiate the mission of the organization.

Research team

As part of JCWO’s achievements is the conformation of its scientific team, which began in 2017. The following are the main researchers:

Eglys González, PhD.

Obtained her Bachelor’s degree in Bioanalysis from the University of Carabobo in Venezuela and her Doctorate in Microbiology from the Venezuelan Institute of Scientific Research (Instituto Venezolano de Investigaciones Científicas – IVIC). During her PhD studies and subsequent Post-doctoral work she worked with Trypanosomatid parasites, specifically with *T. cruzi* and *Leishmania spp.* in vitro and in vivo in murine model. Dr. González was the Research Coordinator of Fundación Jacinto Convit, during the years 2013-2015, participating in the planning of the FJC’s headquarter, and then became a scientific adviser to the Foundation.

Her past experiences include working in the Laboratory of Parasite Physiology at the Center of Biophysics and Biochemistry at IVIC, and the Laboratory of Parasite Enzymology at the University of Los Andes, both located in Venezuela. She was a fellow of the Center for Advanced Studies at IVIC,
and FONACIT (National Fund for Science, Technology and Innovation) in the area of agricultural technology. Dr. González is specialized in Biochemistry and Molecular Parasitology, with various related publications. In the recent years she has gained experience in cancer immunotherapy focusing on Dr. Convit’s cancer vaccine, with one peer reviewed article. Today leads the international efforts as the International Representative of the Jacinto Convit World Organization based in Germany. She is responsible for the international approach for networking, project development and social network management. Also working in the constitution of the institutional bases of JCWO to keep evolving as a non-profit organization.

María José Godoy, PhD.

Obtained her undergraduate degree in Bioanalysis from Universidad Central de Venezuela and her PhD in Biological Science at Universidad Simon Bolívar, with honors. Her awarded thesis was on molecular analysis of the main myeloid acute leukemia, and detection of several genes associated with the response to treatments. She became the Research Coordinator of Fundación Jacinto Convit during the years 2015-2017. Since then she has been a Research Collaborator for the Jacinto Convit World Organization, and author of peer reviewed publications to continue Dr. Convit’s work in cancer immunotherapy.

Her past experiences include working in the Cellular Biology Laboratory at Universidad Simon Bolívar. Dr. Godoy has participated in several trainings and scientific symposiums in several countries and has an international certification in molecular biology from the American Society for Clinical Pathology. She is currently a postdoctoral research associate at the University of Illinois in Chicago. As a collaborator she contributes with the continuing of the development of Dr. Convit’s Immunotheraphy, publishing scientific articles and advising the scientific team regarding the ongoing scientific programs.

Jeismar Carballo, PhD.

Obtained her Bachelor’s degree in Biology from Universidad Central de Venezuela, and received an honorable mention for her thesis. Completed her PhD in Biological Science at Universidad Simón
Bolívar in Venezuela, with honors in her doctoral thesis. During her doctoral studies, her research was focused on: “The effect of the factors released by the peripheral nerves of rat, in the differentiation of neuronal cells and the regeneration of sciatic nerves of rats” and “The neuroprotective effect of Neuregulin-1 in mice, after an ischemic stroke”. Dr. Carballo was Researcher III in Fundación Jacinto Convit during 2018.

Her past experiences include working as a researcher in the Neurosciences Unit of Instituto de Estudios Avanzados, for 8 years, focused on the process of regeneration of the nervous system. Dr. Carballo obtained a scholarship from the German Academic Exchange Service (DAAD) for one (1) year, to carry out part of a research project at the Essen University Hospital-Germany, on the evaluation of drugs after an ischemic stroke. She has participated in several trainings and scientific events, both national and international. She is main author of various publications in indexed journals. Today holds the position of Project Coordinator in Jacinto Convit World Organization Inc. She is responsible for supporting in the international networking efforts, bringing the clinical project of the ConvitVax into many hospitals around the world. As well she supports with the fundraising efforts and the search of institutional alliances.

Expanding the team
An important achievement this year is the conformation of a team of Ad-Honorem Specialists who work with our staff for the preparation and execution of projects.

Scientific Advisor
Adam Brufsky, MD, PhD.
Associate Chief, Division of Hematology/Oncology-UPMC Hillman Cancer Center

Dr. Brufsky received his medical degree and doctorate from the University of Connecticut School of Medicine. He completed his residency in internal medicine at Brigham and Women's Hospital, Harvard Medical School and a fellowship in medical oncology and bone marrow transplantation at the Dana-Farber Cancer Institute. Prior to joining the University of Pittsburgh, Dr. Brufsky served as an
associate physician and instructor in medicine at Harvard Medical School. Dr. Brufsky currently directs the Comprehensive Breast Cancer Program of the UPMC Cancer Centers and the University of Pittsburgh. He manages approximately 30 clinical trials investigating various aspects of breast cancer etiology and treatment. His main clinical interests are in breast cancer medical oncology with a particular interest in metastatic breast cancer.

Ad-Honorem Specialists

Nicolas Acquavella, MD.
Senior Director, R&D Early Clinical Development-Sanofi

Obtained his Medical Degree from the Universidad Central de Venezuela. Dr. Acquayella, is a medical oncologist specialized in the care of patients with melanoma and pancreatic cancer. Currently working in the US as a Senior Director, R&D Early Clinical Development, Immuno-oncology. He has a special interest in to translate novel immunotherapies from the laboratory into first in human clinical studies, and has a vast experience in the preparation of clinical protocols.

Isildinha Reis, PhD.
Research Professor- University of Miami

Dr. Reis earned her master’s degree in statistics from the University of São Paulo, Institute of Mathematics and Statistics, in 1989 and her PhD in biostatistics in 1996 from the University of California at Los Angeles' School of Public Health. Dr. Reis joined the University of Miami and Sylvester in 1999 as Research Assistant Professor in the former Department of Epidemiology and Public Health and was promoted to Research Associate Professor in 2006. Dr. Reis served as director of the Biostatistics Division of the Sylvester Biostatistics and Bioinformatics Core Shared Resource from 2012 to 2015. Dr. Reis has an extensive experience in the design and analysis of clinical trials, basic-science/translational investigations, and epidemiologic studies related to cancer.
Eduardo Cianferra, PharmD,

Cianferra is a Pharmacist of the Universidad Central de Venezuela. Actually, working in the University of Miami at the Memorial Healthcare System as a Research Specialist II. He has more than 5 years of experience in vaccine research, development and production, and is an Clinical Research professional with vast experience in the development of Phase I, II and III clinical trials.

Michelle Yaw, MSc

Obtained a Bachelor's degree from SUNY Stony Brook in Biology, with a second major in English. Went on to obtain a Master's degree from NYU in Management and Systems. She is a Medical Writer with over 12 years of experience in clinical research working in institutions such as NYU Cancer Institute, University of Miami's Cancer Center, and Mayo Clinic.

Jose Alberto Fernandez, MSc

Obtained a Computer Engineer from Universidad Catolica Andres Bello with a MBA Master in Business Administration from Escuela Europea de Negocios. Jose Fernandez as an Ad-Honorem Specialist in the area of technology, mainly in charge of the maintenance, improvements and changes on our website. In the short time he has been supporting JCWO he has made great improvements to our webpage, and have presented high quality proposals. We consolidate this alliance and expect many wonderful improvements for the next year.

Cancer Immunotherapy

The ConvitVax in clinical trials

As part of JCWO’s objectives, a significant effort was made to increase the networking to find new hospitals and begin Phase I clinical trials. Additionally, with the support of the new ad-honorem specialist team, the protocol began to be significantly improved to the highest standards in accordance to the standards of the National Cancer Institute. The first trial is expected to begin in Venezuela, as soon as their top regulatory authority, Instituto Nacional de Higiene Rafael Rangel, gives their final approval. During 2019, around 120 letters were sent to Institutions in the United States, Europe, Latin
America and Asia to carry out the clinical study. Positive response was obtained from an important Hospital in Argentina, with which the procedures and preparation of the agreement for execution were initiated with the collaboration of DLA Piper-Argentina. However, the local medical doctor (principal investigator) who would be in charge of conducting the study, passed away and the co-work could not be continued.

Scientific publications
In November 2019, after several years of hard work from our scientific team, JCWO was pleased and proud to publish in an international peer-reviewed journal its latest scientific work titled “Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment” in Oncotarget (Godoy-Calderón, et al. 2019), with which we consolidate our commitment to scientific research and our search for more effective therapies for cancer patients. Further efforts are being made to publish the results of the toxicity evaluation of the ConvitVax in a murine model.

Funding for JCWO’s programs
This year the process of applications to different grants began. Initially with the support of interns a database was created to consider the organizations and companies to apply to for each of our programs. During 2019 we sent around 100 letters to request for funds (companies, institutions, banks), and 24 grant applications. Until now, we have received rejections from Gateway, Pfizer, Bill and Melinda Foundation, Wellcome, Celgene, Union bank, US-Bank, MDP/Coca-cola Foundation, CIP/Coca-cola Foundation, The Ambrose Monelle, The Conservation, Food and Health, Costco, Schwab charitable, Hansen-2019, Robert Wood Johnson Foundation and Paul G Allen Foundation Grant). However, others are pending for resolution (Carlos Slim, Nippon Foundation, BBVA, MDP-APS USAID, The Conservation, Food and Health-2020, Global Innovation Fund and Hansen-2020). On the other hand, the search for financing has also been carried out via social responsibility of companies in Spain; funds have not yet been obtained. Next year's intensive search for funding will continue in order to find the necessary resources for our programs and cover operational costs.
Internship program

This year we launched an internship program and recruited students from different countries to provide them with opportunities in various disciplines such as language, health care, communications, and design. A total of 8 interns were benefited and the number is expected to increase in the coming months. We are proud of their excellent work and contributions to the organization. This year we receive:

- Andrew Yang – Canada – Language Skilled. Documents review, science series preparation (immunotherapy and molecular diagnosis) for the press room in the web page, interviews with FJC team.
- Lucila Cunningham – United States – Design. The internship did not end.
- Sorianyeli Morin – Venezuela – Design. Design and completion of the Corporate Identity Manual, as well as designed posts for social networks.
- Mariella Marquez – United States – Communication. She conducted a study of the material for social networks and a proposal for those of JCWO. Prepared content and grid for social networks.

Transparency

To increase the transparency levels of the organization we implemented several documents/evaluations:
Effectiveness policy: to establish the effectiveness of the organization during the year; it will be reviewed by the Board of Directors. This policy was established for the first time this year.

President’s Performance Evaluation: an evaluation format was established and completed anonymously by the Board of Directors (excluding the President) to evaluate her performance as President of JCWO. Results of this evaluation were overall very positive.

Effectiveness report for 2018 and 2019: were completed and showed the objectives and the percentage of activities carried out during the year.

Management report: summary of activities and achievements for each of the main objectives of the organization.

Annual budgets: were included in the documentation and completed for 2018, 2019 and estimate 2020.

**Documents Issued**

This year our staff began to improve and/or produce the necessary documents for the identity of the organization as well as legal documents. Listed below are the documents prepared this year:

- Corporate Identity Manual, was developed where the use of the logo, color palette, type of stationery etc. of JCWO is explained in detail.
- Institutional Brochure, was prepared with two versions to present to the institutions of interest.
- Visual Research, showing the facilities of the sister organization Fundación Jacinto Convit.
- End of the year bulletin 2019
- Annual report 2018
- Effectiveness policy (Appendix 2)
- Effectiveness report 2018
- Effectiveness report 2019
- Work plan JCWO-I semester 2019
ANNUAL REPORT 2019
February, 2020

- Work plan closure JCWO-I semester 2019
- Work plan JCWO-II semester 2019
- Work plan closure JCWO-II semester 2019
- Work plan JCWO-I semester 2020
- President’s performance evaluation (Appendix 3)
- Terms of Use-services agreement for JCWO.
- Agreement for the scientific advisor
- Agreement for Ad-Honorem specialist
- Internship program, was activated and all the necessary documentation was prepared to provide the interns with the best advice in each area:
  - Internship offer letter (Appendix 4)
  - Internship evaluation
  - Internship evaluation of supervisor
  - Internship certificate
- Estimated budget for JCWO 2020 (Appendix 5)
- Management report 2019 (Appendix 6)

Networking efforts

The collaboration of institutions is necessary to guarantee the success of the programs. This year, great progress has been made in this area.

AJVaccines

After more than 2 years of conversations, and after the evaluation of their Medical Director, AJVaccines (supplier of BCG and PPD) approved the use of their products in our clinical study with ConvitVax. We expect to establish an agreement in 2020 to guarantee the purchase of their products.
Anesvd at Impact Hub Madrid

The search for allies was carried out to establish a workspace for the project coordinator. Although many companies have been contacted, the support of Impact Hub-Madrid was received under the guidance or cooperation of Anesvd, an organization with more than 50 years of commitment to the Right to health of the most impoverished and forgotten people on the planet. Their scope of intervention focuses on skin diseases such as Buruli ulcer, yaws, lymphatic filariasis or leprosy. They reach places in Sub-Saharan Africa where there are Neglected Tropical Diseases.

Fundación Código Venezuela

This organization in Spain was contacted, continuing with the search for workspaces, although they could not offer this benefit, volunteer offers for JCWO were published on their website, it is expected to continue strengthening ties with this Foundation.

Centro Nacional de Investigaciones Oncológicas

The search for an alliance with organizations in the area of cancer research began. The Centro Nacional de Investigaciones Oncológicas (CNIO) in Madrid-Spain was the first contacted. The Neuroblastomas line for the MDP was achieved with a research group, however the conditions for the shipment have not yet been achieved. A meeting is being coordinated with the directive of the center that will be held in January 2020. A great alliance with this Center that benefits both programs is expected.

Dr. Francisco Kerdel-Vegas

At the end of 2019, our team had the exceptional opportunity to interview Dr. Kerdel-Vegas, a renowned physician, dermatologist, diplomat and professor, born in Venezuela, currently residing in Spain. Worked for more than 25 years with Dr. Convit in research and clinic on infectious diseases. Together they trained new generations of specialists and founded an NGO to promote and finance studies in neglected dermatologic diseases. A new alliance for the knowledge and development of the organization was reached. Full interview will soon be published in our Press Room.
Visits to allies and new Ad-Honorem Specialists

To strengthen the alliances and collaborations achieved, the President of the organization visited the Camero & Company team in the United States. Also, Dr. Isildinha Reis, collaborator of the clinical project in statistics and Eduardo Cianferra, PharmD, collaborator in the operational development of the clinical project.

Social Networks

At the beginning of 2018 JCWO started the management of social networks such as Twitter, LinkedIn, Instagram and Facebook. Publications were made every day about our work and information of interest, increasing continuously the number of followers and interactions within the networks. We continue to improve the content in the networks with the collaboration of interns in the area of design and communications. However, it is a very demanding area that requires continuous support.

In 2019, social networks underwent several modifications because there is no staff fully dedicated to this area. At the end of the year, interns collaborated on the designs to improve the presence of the organization in social networks and the number of posts was reduced to 1-2 daily. The interaction between the followers has been maintained. This year around 200 new followers were reached among the social networks of Instagram, Twitter, LinkedIn and Facebook.

Patent

A patent is a form of intellectual property that gives its owner the right to exclude others from making, using, selling, and importing an invention for a limited period of time, usually twenty years. Based on Dr. Convit’s work and our institutional philosophy, all our services are free of cost for the patients, in order to benefit the most underprivileged population around the world. Therefore, in an effort to protect the legacy of Dr. Convit and making sure that his inventions are of free access, JCWO patented the cancer vaccine formulation, titled "AN IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER AND METHODS OF PREPARING THE SAME" under the number 10092451-50214648-0000.
The protection of the invention was initiated in Venezuela by FJC on May 10th 2016, then the International application published under the Patent Cooperation Treaty was filed by JCWO in November 16th 2017. As the law indicates, one year after JCWO had to decide the countries in which the protection should be filed, and since November 2018 the Patent Cooperation Treaty application was introduced in the US, Brazil, Colombia, Chile and Europe. The specific dates for the 2018 were as follows: November 9th in Brazil, November 1st in the US, December 10th in Europe, December 14th in Colombia and December 28th in Chile.

In 2019 the processes continued their course without the addition of any other country to the patent process. Payment of request for substantive examination for the Chilean application no. 2018-3184 and payment of request for substantive examination, payment of excess claims, and/or voluntary amendment due for the Colombian application no. nc2018/0013350, were completed.

The JCWO's 2018 financial information

<table>
<thead>
<tr>
<th>ITEMS</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
</tr>
<tr>
<td>Contributions, gifts, grants, and similar</td>
<td>14.339,00</td>
</tr>
<tr>
<td>amounts received</td>
<td></td>
</tr>
<tr>
<td>Investment income</td>
<td>467,00</td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td>14.806,00</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
</tr>
<tr>
<td>Salaries, other compensation, and employee</td>
<td>4.791,00</td>
</tr>
<tr>
<td>benefits</td>
<td></td>
</tr>
<tr>
<td>Professional fees and other payments to</td>
<td>11.200,00</td>
</tr>
<tr>
<td>independent contractors</td>
<td></td>
</tr>
<tr>
<td>Printing, publications, postage, and</td>
<td>3.400,00</td>
</tr>
<tr>
<td>shipping</td>
<td></td>
</tr>
<tr>
<td>Other expenses</td>
<td>13.468,00</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>32.859,00</td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td></td>
</tr>
<tr>
<td>Excess or (deficit) for the year</td>
<td>18.053,00</td>
</tr>
<tr>
<td>Net assets or fund balances at beginning</td>
<td>182.343,00</td>
</tr>
<tr>
<td>of year</td>
<td></td>
</tr>
<tr>
<td>Net assets or fund balances at end of year</td>
<td>164.290,00</td>
</tr>
</tbody>
</table>
## Appendix 1. Donations received

<table>
<thead>
<tr>
<th>Institution</th>
<th>Date</th>
<th>Type of donation</th>
<th>Amount ($)</th>
<th>Purpose of the donation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government of Japan</td>
<td>02/21/2019</td>
<td>Monetary</td>
<td>64,890.00</td>
<td>Equipment</td>
</tr>
<tr>
<td>Kalstein</td>
<td>05/03/2019</td>
<td>In Kind</td>
<td>870.00</td>
<td>Equipment</td>
</tr>
<tr>
<td>Repsol</td>
<td>06/09/2019</td>
<td>Monetary</td>
<td>5,050.00</td>
<td>Equipment</td>
</tr>
<tr>
<td>Foundation for endemic disease</td>
<td>10/28/2019</td>
<td>Monetary</td>
<td>31,953.33</td>
<td>Operational</td>
</tr>
<tr>
<td>Amazon Smile</td>
<td>Accumulative during the year</td>
<td>Monetary</td>
<td>53,91</td>
<td>General</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td><strong>102,817.21</strong></td>
<td></td>
</tr>
</tbody>
</table>
Jacinto Convit World Organization, Inc. Effectiveness Policy

Charity Effectiveness Policy

WHEREAS, Jacinto Convit World Organization Inc. (JCWO) board of directors seeks to establish a policy on effectiveness assessment to help ensure that the organization has defined, measurable goals and objectives in place to evaluate the success and impact of its program(s) in fulfilling these goals and objectives,

IT IS THEREFORE RESOLVED THA JCWO board of directors adopts the following policy:
1. At least once every two years, JCWO will review its goals and objectives toward achieving its mission and will complete a performance and effectiveness assessment of its programs based on that review.
2. Such an assessment will be conducted under the authority of JCWO Board.
3. JCWO Board will receive a written report of this assessment:
   (a) Describing the activities that JCWO undertook in the prior two years to achieve its goals and objectives,
   (b) Identifying the measures used to assess JCWO’s effectiveness in achieving its goals and objectives,
   (c) Analyzing the effectiveness of JCWO’s programs in achieving the Organization's goals and objectives,
   (d) Recommending future actions JCWO might take to increase effectiveness based on the findings.
4. At the conclusion of this process, JCWO’s will revise the goals and objectives for the Organization, as needed, for the upcoming term and will suggest means of measuring them.
Please provide your written assessment of the President of Jacinto Convit World Organization, Inc. for 2018.

Please return your completed form via email to JCWO at jcwo@jacintoconvit.org or in an envelope marked “CONFIDENTIAL” to the address below:

Jacinto Convit World Organization, Inc.
508 Misty Oaks Dr.
Pompano Beach, FL 33069

Please indicate your responses to the statements below using the following scale:

1  Strongly agree
2  Agree
3  Not currently relevant, unable to evaluate, or no opinion
4  Disagree
5  Strongly disagree

### STATEMENTS

<table>
<thead>
<tr>
<th>5</th>
<th>Strongly disagree</th>
</tr>
</thead>
</table>

### RATINGS

<table>
<thead>
<tr>
<th>1</th>
<th>Strongly agree</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Agree</td>
</tr>
<tr>
<td>3</td>
<td>Not currently relevant, unable to evaluate, or no opinion</td>
</tr>
<tr>
<td>4</td>
<td>Disagree</td>
</tr>
<tr>
<td>5</td>
<td>Strongly disagree</td>
</tr>
</tbody>
</table>

### COMMENTS

Please attach additional pages for comments, if needed

<table>
<thead>
<tr>
<th>1</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. **STRATEGIC PLANNING.** Ensures the development of a long-term strategy. Establishes objectives and plans that meet the needs of beneficiaries, donors, employees and all other parts, and ensures consistent and timely progress toward strategic objectives. Obtains and allocates resources consistent with strategic objectives. Reports regularly to the Board on progress made toward the strategic plan.

<table>
<thead>
<tr>
<th>1</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. **LEADERSHIP.** Develops and communicates a clear and consistent vision of the organization's goals and values, and ensures that they are well understood, widely supported and effectively implemented within the organization. JCWO a corporate culture that encourages, recognizes and rewards leadership, excellence and innovation. Ensures a culture that promotes ethical practices, individual integrity, and cooperation.

<table>
<thead>
<tr>
<th>1</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## ANNUAL REPORT 2019

February, 2020

<table>
<thead>
<tr>
<th>5</th>
<th>Strongly disagree</th>
<th>STATEMENTS</th>
<th>RATINGS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 Strongly agree</td>
<td>2 Agree</td>
</tr>
<tr>
<td>3.</td>
<td>FINANCIAL RESULTS. Establishes and achieves appropriate annual and longer-term financial performance goals. Ensures the development and maintenance of appropriate systems to protect the organization's assets and assure effective control of operations.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>MANAGEMENT OF OPERATIONS. Ensures high quality, cost-effective management of the day-to-day business affairs of the organization. Promotes continuous improvement of the quality, value and competitiveness of the organization's programs, intellectual property and business systems. Encourages and rewards creative solutions to business and management challenges.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>MANAGEMENT DEVELOPMENT AND SUCCESSION PLANNING. Develops, attracts, retains and motivates an effective and unified senior management team. Ensures that programs for management development and succession planning have the required resources and direction to grow the future leaders of the company.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>HUMAN RESOURCES. Ensures the development of effective programs for the recruitment, training, compensation, retention and motivation of personnel, and the availability of human resources necessary to achieve the organization's objectives. Establishes and monitors programs to promote workplace diversity. Provides for appropriate recognition of the achievements of individuals and groups.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>SPOKESPERSON. Serves as chief spokesperson for the organization, communicating effectively with the board of directors, donors, employees, suppliers and beneficiaries. Represents the organization effectively in relationships within industry, the government and financial community.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>BOARD RELATIONS. Works closely with the Board to keep directors informed on the state of the business, development of key management talent, crucial issues relating to the organization, and the organization's progress toward the achievement of operating plan and strategic plan milestones.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td>Please provide any overall comments regarding the</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please attach additional pages for comments, if needed
<table>
<thead>
<tr>
<th>5</th>
<th>Strongly disagree</th>
<th>STATEMENTS</th>
<th>RATINGS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Strongly agree</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Agree</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Not currently relevant, unable to evaluate, or no opinion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Disagree</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Strongly disagree</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

President’s performance in 2018:  

<table>
<thead>
<tr>
<th>10. Please indicate any key challenges in the next year:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>11. What key message would you like for the Board to deliver when communicating the evaluation of the President:</th>
</tr>
</thead>
</table>
Appendix 4. Internship offer letter

JACINTO CONVIT WORLD ORGANIZATION, INC.

[Date]

[Intern Name]
[Street Address]
[City, State Zip Code]

Re: Internship

Dear [Intern Name]:

On behalf of Jacinto Convit World Organization, Inc., (the “Organization”), we are excited to offer you the opportunity to join the Organization as an intern. This letter sets out the terms of your internship with the Organization. Should you accept this offer, the internship period is anticipated to run from [Start Date] to [End Date].

During your internship, you will be able to participate in the workings of the Organization in order to learn more about the field of [__________]. We hope to be able to expose you to possible career paths and interests. During your internship you will be exposed to a variety of assignments with experienced employees designed to further your goal of gaining skills and experience in the field. These assignments will be documented in the Project Assignments to Interns in the form attached to this Agreement as Appendix I.

While we are pleased to be able to provide this hands-on training experience, as we have discussed, as an intern you are not considered an employee and you are not entitled to, and do not expect, wages for the time spent by you during this training opportunity. As an intern, you will not be eligible for any compensation or Organization sponsored benefits. You understand that the internship is not an offer of employment, now or in the future. The Organization reserves the right to terminate or shorten the internship in its business discretion.

We are excited about having you intern with us and we will do our best to teach you what we know along the way and to make this a great learning experience. Because we will be sharing proprietary information with you about the Organization and because you may be assisting in creating proprietary materials for the Organization as part of your internship, you will be required to sign and return the Intern Proprietary Information and Inventions Assignment attached hereto as Exhibit A.

By signing below, you acknowledge and agree that the Organization shall not be liable for any damages arising out of your participation in this internship, or any programs, activities or events in which you participate in connection with this internship, including any damages arising from personal injuries or accidents sustained by you in, on or about the premises or equipment of the Organization during the term of this internship.
[Intern Name], we look forward to working with you! This internship offer will remain open until the close of business on [Date]. Please sign and date this letter on the spaces provided below to acknowledge your acceptance of Organization’s offer on the terms set forth in this letter.

Sincerely,

Jacinto Convit World Organization, Inc.

By: ______________________________
Name: ______________________________
Title: ______________________________

AGREED AND ACCEPTED.

Date: ___________, 2019

[Intern Name]
Appendix I

PROJECT ASSIGNMENT

Services and Deliverables to be Provided

- Bibliographic revision of the material related to Dr. Convit’s work and JCWO to a basic comprehension of the current programs and efforts.

- Revision and feeding of the medical institutions database, related to the networking efforts to obtain partners for the programs.

- Follow up on proposals and requests made by JCWO to add supporters and collaborators to the cause.

- Search for potential beneficiaries (public hospitals or clinics) of the Molecular Diagnostics Program in the Latin American region, as well as partner institutions.

- Search for quotes to continue feeding and updating the budget of JCWO projects.

- Identify suitable funding applications and grant openings for programs developed by JCWO.

- Contribute with the fundraising efforts, contacting and applying to companies, banks, foundations, and related institutions that give support to NGOs and the specific type of work carried out by JCWO. This shall include monetary and any other types of support.

- Support in efforts to find pro-bono services, assessment, or required material and equipment.

- Perform related activities assigned by the International Representative and Scientific Officer.

- Give a final presentation and provide a written report at the end of the internship, regarding the work completed throughout the experience and recommendations. The presentation will be done by video conference to JCWO staff and the President of the organization.

- Bibliographic revision of the material related to Dr. Convit’s work and JCWO to a basic comprehension of the current programs and efforts.

- Revision and feeding of the medical institutions database, related to the networking efforts to obtain partners for the programs.
NOTE: This Project Assignment is governed by the terms of an Internship Agreement in effect between Organization and Intern. Any term in this Project Assignment that is inconsistent with that agreement is invalid.

IN WITNESS WHEREOF, the parties are signing this Project Assignment as of the later date below.

“Organization”

Jacinto Convit World Organization, Inc.

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

“Intern”

[Intern Name]

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________
This Agreement sets forth in writing certain understandings and procedures applicable to my services to Jacinto Convit World Organization, Inc. (the “Organization”) and these understandings and procedures apply from the date of my initial service to the Organization (my “Effective Date”) even if this Agreement is signed by me and Organization after the Effective Date.

1. **Duties.** In return for the consideration set forth in the terms of my Offer Letter, I hereby agree to perform those duties for Organization as Organization may designate from time to time. During my services to the Organization, I further agree that I will (i) devote my best efforts to the interests of Organization, and (ii) not engage in other services or in any conduct that could either be in direct conflict with Organization’s interests or that could cause a material and substantial disruption to Organization and (iii) otherwise abide by all of Organization’s policies and procedures as they may be established and updated from time to time. Furthermore, I will not (a) reveal, disclose or otherwise make available to any unauthorized person any Organization password or key, whether or not the password or key is assigned to me or (b) obtain, possess or use in any manner an Organization password or key that is not assigned to me. I will use my best efforts to prevent the unauthorized use of any laptop or personal computer, peripheral device, cell phone, smartphone, personal digital assistant (PDA), software or related technical documentation that the Organization issues to me. I will not input, load or otherwise attempt any unauthorized use of software in any Organization computer or other device, whether or not the computer or device is assigned to me.

2. **“Proprietary Information” Definition.** “Proprietary Information” means (a) any information that is confidential or proprietary, technical or non-technical information of Organization, including for example and without limitation, information that is an Organization Innovation or is related to any Organization Innovations (as defined in Section 5 below), concepts, techniques, processes, methods, systems, designs, computer programs, source documentation, trade secrets, formulas, development or experimental work, work in progress, forecasts, proposed and future products, marketing plans, business plans, customers and suppliers, employee information (such as compensation data and performance reviews) and any other nonpublic information that has commercial value and (b) any information Organization has received from others that Organization is obligated to treat as confidential or proprietary, which may be made known to me by Organization, a third party or otherwise that I may learn during my services to the Organization.

3. **Ownership and Nondisclosure of Proprietary Information.** All Proprietary Information and all worldwide patents (including, but not limited to, any and all patent applications, patents, continuations, continuation-in-parts, reissues, divisionals, substitutions, and extensions), copyrights, mask works, trade secrets and other worldwide intellectual property and other rights in and to the Proprietary Information are the property of Organization, Organization’s assigns, Organization’s customers and Organization’s suppliers, as applicable. Subject to Section 12 (Defend Trade Secrets Act), I will not disclose any Proprietary Information to anyone outside Organization, and I will use and disclose Proprietary Information to those inside Organization only as necessary to perform my duties for Organization. Nothing in this Agreement will limit my ability to provide truthful information to any government agency regarding potentially unlawful conduct. If I have any questions as to whether information is Proprietary Information, or to whom, if anyone, inside Organization, any Proprietary Information may be disclosed, I will ask my manager at Organization.
4. “Innovations” Definition. In this Agreement, “Innovations” means all discoveries, designs, developments, improvements, inventions (whether or not protectable under patent laws), works of authorship, information fixed in any tangible medium of expression (whether or not protectable under copyright laws), trade secrets, know-how, ideas (whether or not protectable under trade secret laws), mask works, trademarks, service marks, trade names and trade dress.

5. Disclosure and License of Prior Innovations. I have listed on Exhibit A (Prior Innovations) attached hereto all Innovations relating in any way to Organization’s business or demonstrably anticipated research and development or business (the “Organization-Related Innovations”), that were conceived, reduced to practice, created, derived, developed, or made by me alone or jointly with others prior to my Effective Date and to which I retain any ownership rights or interest (these Organization-Related Innovations collectively referred to as the “Prior Innovations”). I represent that I have no rights in any Organization-Related Innovations other than those Prior Innovations listed in Exhibit A (Prior Innovations). If nothing is listed on Exhibit A (Prior Innovations), I represent that there are no Prior Innovations as of my Effective Date. I hereby grant to Organization and Organization’s designee a royalty-free, transferable, irrevocable, worldwide, fully paid-up license (with rights to sublicense through multiple tiers of sublicenses) to fully use, practice and exploit all patent, copyright, moral right, mask work, trade secret and other intellectual property rights relating to any Prior Innovations that I incorporate, or permit to be incorporated, in any Innovations that I, solely or jointly with others, create, derive, conceive, develop, make or reduce to practice within the scope of my services for the Organization (the “Organization Innovations”). Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated, any Prior Innovations in any Organization Innovations without Organization’s prior written consent.

6. Disclosure and Assignment of Organization Innovations. I will promptly disclose and describe to Organization all Organization Innovations. I hereby do and will irrevocably assign to Organization or Organization’s designee all my right, title, and interest in and to any and all Organization Innovations, which assignment operates automatically upon the conception of the Organization Innovations. To the extent any of the rights, title and interest in and to Organization Innovations cannot be assigned by me to Organization, I hereby grant to Organization an exclusive, royalty-free, transferable, irrevocable, worldwide, fully paid-up license (with rights to sublicense through multiple tiers of sublicenses) to fully use, practice and exploit those non-assignable rights, title and interest, including, but not limited to, the right to make, use, sell, offer for sale, import, have made, and have sold, the Organization Innovations. To the extent any of the rights, title and interest in and to Organization Innovations can neither be assigned nor licensed by me to Organization, I hereby irrevocably waive and agree never to assert the non-assignable and non-licensable rights, title and interest against Organization, any of Organization’s successors in interest, or any of Organization’s customers.

7. Future Innovations. I will disclose promptly in writing to Organization all Innovations conceived, reduced to practice, created, derived, developed, or made by me during my services for the Organization and for three (3) months thereafter, whether or not I believe the Innovations are subject to this Agreement, to permit a determination by Organization as to whether or not the Innovations are or should be considered Organization Innovations. Organization will receive that information in confidence.

8. Notice of Nonassignable Innovations in California. This Agreement does not apply to an Innovation that qualifies fully as a non-assignable invention under the provisions of Section 2870 of the California Labor Code. I have reviewed the notification in Exhibit B (Limited Exclusion Notification) and agree that my signature on this Agreement acknowledges receipt of the notification.
9. Cooperation in Perfecting Rights to Organization Innovations. I agree to perform, during and after my service to the Organization, all acts that Organization deems necessary or desirable to permit and assist Organization, at its expense, in obtaining and enforcing the full benefits, enjoyment, rights and title throughout the world in the Organization Innovations and all intellectual property rights therein as provided to Organization under this Agreement. If Organization is unable for any reason to secure my signature to any document required to file, prosecute, register or memorialize the assignment of any rights or application or to enforce any right under any Organization Innovations as provided under this Agreement, I hereby irrevocably designate and appoint Organization and Organization’s duly authorized officers and agents as my agents and attorneys-in-fact to act for and on my behalf and instead of me to take all lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, issuance, and enforcement of rights under the Innovations, all with the same legal force and effect as if executed by me. The foregoing is deemed a power coupled with an interest and is irrevocable.

10. Return of Materials. At any time upon Organization’s request, and when my service to the Organization is over, I will return all materials (including, without limitation, documents, drawings, papers, diskettes and tapes) containing or disclosing any Proprietary Information (including all copies thereof), as well as any keys, pass cards, identification cards, computers, printers, pagers, cell phones, smartphones, personal digital assistants or similar items or devices that Organization has provided to me. I will provide Organization with a written certification of my compliance with my obligations under this Section 10.

11. No Violation of Rights of Third Parties. During my service to the Organization, I will not (a) breach any agreement to keep in confidence any confidential or proprietary information, knowledge or data acquired by me prior to my service to the Organization or (b) disclose to Organization, or use or induce Organization to use, any confidential or proprietary information or material belonging to any previous employer or any other third party. I am not currently a party, and will not become a party, to any other agreement that is in conflict, or will prevent me from complying, with this Agreement.

12. Defend Trade Secrets Act. Pursuant to the Defend Trade Secrets Act of 2016, I acknowledge that I shall not have criminal or civil liability under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, if I file a lawsuit for retaliation by the Organization for reporting a suspected violation of law, I may disclose the trade secret to my attorney and may use the trade secret information in the court proceeding, if I (X) file any document containing the trade secret under seal and (Y) do not disclose the trade secret, except pursuant to court order.

13. Survival. This Agreement (a) shall survive my services to the Organization; (b) does not in any way restrict my right to resign or the right of Organization to terminate my service at any time, for any reason or for no reason; (c) inures to the benefit of successors and assigns of Organization; and (d) is binding upon my heirs and legal representatives.

14. Injunctive Relief. I agree that if I violate this Agreement, Organization will suffer irreparable and continuing damage for which money damages are insufficient, and Organization is entitled to injunctive relief, a decree for specific performance, and all other relief as may be proper (including money damages if appropriate), to the extent permitted by law, without the need to post a bond.
15. **Notices.** Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows, with notice deemed given as indicated: (a) by personal delivery, when actually delivered; (b) by overnight courier, upon written verification of receipt; (c) by facsimile transmission, upon acknowledgment of receipt of electronic transmission; ; (d) by email, effective (A) when the sender receives an automated message from the recipient confirming delivery or (B) one hour after the time sent (as recorded on the device from which the sender sent the email) unless the sender receives an automated message that the email has not been delivered, whichever happens first, but if the delivery or receipt is on a day which is not a business day or is after 5:00 pm (addressee’s time) it is deemed to be received at 9:00 am on the following business day; or (e) by certified or registered mail, return receipt requested, upon verification of receipt. Notices to me shall be sent to any address in Organization’s records or other address as I may provide in writing. Notices to Organization shall be sent to Organization’s Human Resources Department or to another address as Organization may specify in writing.

16. **Governing Law; Forum.** The laws of the United States of America and the State of California govern all matters arising out of or relating to this Agreement without giving effect to any conflict of law principles. Organization and I each irrevocably consent to the exclusive personal jurisdiction of the federal and state courts located in San Francisco County, California, as applicable, for any matter arising out of or relating to this Agreement, except that in actions seeking to enforce any order or any judgment of the federal or state courts located in San Francisco County, California, personal jurisdiction will be nonexclusive. Additionally, notwithstanding anything in the foregoing to the contrary, a claim for equitable relief arising out of or related to this Agreement may be brought in any court of competent jurisdiction. For the avoidance of doubt, the foregoing terms will control over any conflicting terms in my offer letter.

17. **Severability.** If an arbitrator or court of law holds any provision of this Agreement to be illegal, invalid or unenforceable, (a) that provision shall be deemed amended to provide Organization the maximum protection permitted by applicable law and (b) the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected.

18. **Waiver; Modification.** If Organization waives any term, provision or breach by me of this Agreement, such waiver shall not be effective unless it is in writing and signed by Organization. No waiver shall constitute a waiver of any other or subsequent breach by me. This Agreement may be modified only if both Organization and I consent in writing.

19. **Assignment.** The rights and benefits of this Agreement shall extend to all successors and assigns of the Organization, whether by merger, reorganization, sale of assets, operation of law or otherwise.

20. **Entire Agreement.** This Agreement, including any agreement to arbitrate claims or disputes relating to my service to the Organization that I may have signed in connection with my service to the Organization, represents my entire understanding with Organization with respect to the subject matter of this Agreement and supersedes all previous understandings, written or oral.
I certify and acknowledge that I have carefully read all of the provisions of this Agreement and that I understand and will fully and faithfully comply with such provisions.

JACINTO CONVIT WORLD ORGANIZATION, [NAME]
INC.

By: ________________________________
Name: ________________________________
Title: ________________________________
Dated: ________________________________

By: ________________________________
Dated: ________________________________
Appendix 5. Estimated budget

ESTIMATED BUDGET FOR JCWO 2020

<table>
<thead>
<tr>
<th>ITEMS</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Estimated Revenue</strong></td>
<td></td>
</tr>
<tr>
<td>Private Institutions</td>
<td>50,000,00</td>
</tr>
<tr>
<td>Foreign Government</td>
<td>100,000,00</td>
</tr>
<tr>
<td>Fundraising Platforms</td>
<td>1000,00</td>
</tr>
<tr>
<td>Individual Contributions</td>
<td>500,00</td>
</tr>
<tr>
<td><strong>Total Projected Income</strong></td>
<td>151,500,00</td>
</tr>
<tr>
<td><strong>Estimated Expenses</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Molecular Diagnostics Program</strong></td>
<td></td>
</tr>
<tr>
<td>Reagents</td>
<td>15,000,00</td>
</tr>
<tr>
<td>Supplies</td>
<td>10,000,00</td>
</tr>
<tr>
<td>Equipment</td>
<td>15,000,00</td>
</tr>
<tr>
<td>Others</td>
<td>3,000,00</td>
</tr>
<tr>
<td><strong>Cancer Immunotherapy Program</strong></td>
<td></td>
</tr>
<tr>
<td>Reagents</td>
<td>50,000,00</td>
</tr>
<tr>
<td>Supplies</td>
<td>15,000,00</td>
</tr>
<tr>
<td>Others</td>
<td>3,000,00</td>
</tr>
<tr>
<td><strong>Administrative</strong></td>
<td></td>
</tr>
<tr>
<td>Personnel</td>
<td>40,000,00</td>
</tr>
<tr>
<td>Others</td>
<td>500,00</td>
</tr>
<tr>
<td><strong>Total Estimated Expenses</strong></td>
<td>151,500,00</td>
</tr>
</tbody>
</table>
Specific objectives and activities

1. Inclusion of the ConvitVax into Phase I clinical trials for breast cancer in female patients.

   Activities:
   - Evaluate the requirements necessary to register the vaccine project in the NIH-USA and in the AEMPS-Spain.
   - Prepare the necessary documentation to submit the project for review in the NIH-USA and in the AEMPS-Spain.
   - Arrange support to obtain the BCG vaccines and PPD tests needed for the execution of the clinical trials.
   - Arrange support for the management and analysis of the data from the clinical trials.

2. Arrange partnership agreements with health centers that can execute the clinical trials using the ConvitVax.

   Activities:
   - Find new cooperative institutions with whom JCWO can partner for performing a clinical trial inside and outside the US.
   - Sign Collaboration Agreement with Hospital de Argentina for clinical trials execution.
   - Arrange the material and send partnership requests to the institutions listed in the data base, and keep contact with those that agree to participate.
3. Raising funds to support the clinical trials and all the activities and research studies developed by JCWO.

Activities:

- Develop projects to register within the organizations that give grants for research or clinical studies.
- As soon as an agreement for clinical trial is achieved, raise funds for this purpose.

4. Obtain all the permit for the execution of clinical trials in Argentina.

Activities:

- Prepare the documentation and deliver to the bioethics committee of Eva Peron Hospital.
- Prepare the documentation and deliver to the IBYME.
- Prepare the documentation and deliver to the ANMAT.

5. Arrange collaboration agreements with international organizations, academia, and multilaterals that can support the programs of JCWO.

Activities:

- Arrange agreements with institutions or Universities that can help JCWO to include international voluntaries or interns to support the programs.

6. Conformation of an international scientific committee for JCWO that acts as advisor of scientific projects.

Activities:

- Start a New search for possible advisors of the scientific projects of JCWO.
- Contact and keep up conversations with all included researcher and determine whether they are interested in collaborating.
- If a positive response is given to our collaborative request, then arrange all related to the setting up of an agreement.
7. Support all activities related with the media for JCWO.

Activities:
- Preparation of JCWO identity documents such as brochure, identity manual, etc.
- Feed up and keep up to date web page with appropriate information and content of interest.
- Give support in the process of feeding the social networks of JCWO.

8. Complete the review of all raw material of Dr. Convit.

Activities:
- Classify, safeguard and determine the use of Dr. Convit's raw material.

9. Scientific and monetary support.

Activities:
- Perform the JCWO registration at SAM to participate in obtaining US government funds.
- Start the NIH search for grants in which the organization can participate.

10. Scientific and monetary support to our sister organization FJC and the development of their programs.

Activities:
- Maintain a good communication with the scientific team of FJC to improve the projects developed by both organizations, and keep up to date with the activities performed within both organizations.
- Support the projects developed in FJC by raising funds and/or searching for donations directly related to these projects.
- Make and maintain international contacts to support the adequate execution of the research studies to be performed by the scientific team of FJC.

11. Train interns in different areas of the organization (Health care, language, communications, design, etc.)
Activities:

- Prepare documents and activities for different internships. Publish posts on platforms for the recruitment of interns.
- Carry out continuous monitoring of the different internship activities.
Management Indicators for 2019

Goals-2019

- Goals
- Achieved
Number of beneficiaries each month

<table>
<thead>
<tr>
<th>Month</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>5.00</td>
</tr>
<tr>
<td>February</td>
<td>1.00</td>
</tr>
<tr>
<td>March</td>
<td>3.00</td>
</tr>
<tr>
<td>April</td>
<td>4.00</td>
</tr>
<tr>
<td>May</td>
<td>3.00</td>
</tr>
<tr>
<td>June</td>
<td>5.00</td>
</tr>
<tr>
<td>July</td>
<td>4.00</td>
</tr>
<tr>
<td>August</td>
<td>3.00</td>
</tr>
<tr>
<td>September</td>
<td>4.00</td>
</tr>
<tr>
<td>October</td>
<td>3.00</td>
</tr>
<tr>
<td>November</td>
<td>2.00</td>
</tr>
<tr>
<td>December</td>
<td>1.00</td>
</tr>
</tbody>
</table>
ANNUAL REPORT 2019

February, 2020

Number of new followers

Number

January  February  March  April  May  June  July  August  September  October  November  December